[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 222
1. Brueckl WM, Schoeberl A, Wirtz RM, Murray S, Hahn EG, Wiest GH: Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol; 2008 Mar;3(3):314-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
  • A 37-year-old female never smoker with metastatic large cell carcinoma of the lung had a partial response to a second line palliative therapy with the EGF-R tyrosine kinase inhibitor erlotinib after platinum based first line therapy failed.
  • To our knowledge, this is the first report about a high vascular-endothelial growth factor-A expression in the tumor of a patient responding to an EGF-R inhibitor postulating that there might be a link between both tyrosine kinase pathways.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / drug effects. Lung Neoplasms / metabolism. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adult. Erlotinib Hydrochloride. Fatal Outcome. Female. Follow-Up Studies. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Mutation. Protein Kinase Inhibitors / therapeutic use. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317076.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


2. Tokat AO, Yüksel C, Ozdemir Kumbasar O, Güngör A: [Association of combined small cell and large cell lung cancer with Lambert-Eaton myasthenic syndrome: case report]. Tuberk Toraks; 2005;53(2):177-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of combined small cell and large cell lung cancer with Lambert-Eaton myasthenic syndrome: case report].
  • Lambert-Eaton myasthenic syndrome (LEMS) is a rare type of neuromusculer conduction disorder.
  • This disease can be seen with lung cancer and, it is associated with otoimmunity.
  • Among the symptoms of lung cancer LEMS can be seen, but it is very rare.
  • In this case, LEMS symptoms were analyzed before lung cancer symptoms.
  • [MeSH-major] Lambert-Eaton Myasthenic Syndrome / diagnosis
  • [MeSH-minor] Aged. Carcinoma, Large Cell / complications. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiography. Carcinoma, Small Cell / complications. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / radiography. Diagnosis, Differential. Humans. Lung Neoplasms / complications. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Male. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiography


3. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M: Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res; 2008 Feb 15;14(4):1059-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: A series of 116 NETs were collected, including 58 gastroenteropancreatic (GEP) and 58 lung NETs.
  • RESULTS: By means of both quantification by real-time PCR and immunohistochemistry, a higher TS expression in pulmonary small cell lung cancer and large cell NEC compared with typical and atypical carcinoids was observed (P < 0.01).
  • [MeSH-major] Digestive System Neoplasms / enzymology. Drug Resistance, Neoplasm / physiology. Lung Neoplasms / enzymology. Neuroendocrine Tumors / enzymology. Thymidylate Synthase / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281538.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Hall NC, Kloos RT: PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol; 2007 Jul;51(5):793-805
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging in differentiated thyroid cancer: where does it fit and how do we use it?
  • Positron emission tomography (PET) is a rapidly evolving imaging modality that has gained widespread acceptance in oncology, with several radionuclides applicable to thyroid cancer.
  • Thyroid cancer patients have been studied most commonly using 18F-Fluorodeoxyglucose (FDG)-PET, with perhaps the greatest utility being the potential localization of tumor in differentiated thyroid cancer (DTC) patients who are radioiodine whole body scan (WBS) negative and thyroglobulin (Tg) positive.
  • However, studies documenting improvements in survival and tumor recurrence attributable to FDG-PET imaging in thyroid cancer patients are lacking.
  • Specific case examples of thyroid cancer patients who appear to have benefited from FDG-PET imaging do exist, while less data are available in the setting of anaplastic or medullary thyroid carcinoma.
  • [MeSH-major] Carcinoma, Medullary / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Thyroid Neoplasms / radionuclide imaging
  • [MeSH-minor] Cell Differentiation. Humans. Incidental Findings. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / radionuclide imaging. Sensitivity and Specificity. Thyroglobulin / blood. Thyroid Nodule / radionuclide imaging. Whole Body Imaging

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891243.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin
  • [Number-of-references] 85
  •  go-up   go-down


5. Ambrosini V, Quarta C, Zinzani PL, Nanni C, Fini M, Torricelli P, Giavaresi G, D'Errico-Grigioni A, Malvi D, Franchi R, Fanti S: 18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. Q J Nucl Med Mol Imaging; 2010 Dec;54(6):689-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Food and Drug Administration (FDA) approved the use of Sorafenib, an oral multikinase inhibitor, for advanced renal carcinoma and unresectable hepatocellular carcinoma.
  • On-going studies are investigating the efficacy of Sorafenib in other solid tumours such as melanoma and non-small cells lung carcinoma and pre-clinical models showed the efficacy of treatment with Sorafenib in murine models of renal cells carcinoma, breast cancer, colon carcinoma and melanoma.
  • The aim of the present study was to assess the efficacy of Sorafenib in murine models of human anaplastic large cells lymphoma (ALCL) and Hodgkin lymphoma (HD).
  • Cells were assayed for Caspase-3 to measure apoptosis.
  • RESULTS: Sorafenib efficacy on cells proliferation and apoptosis (IC50: HD=0.0343 mg/L; ALCL=0.319 mg/L) was confirmed in vitro.
  • Caspase-3 production showed a dose-dependent trend reaching significantly higher values for 0.046 mg/L and 0.465 mg/L drug concentrations in both cell lines.
  • CONCLUSION: Sorafenib showed a good cytotoxic effect in vitro especially on human HD cell line, but these findings were not confirmed in vivo.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / veterinary. Humans. Mice. Niacinamide / analogs & derivatives. Phenylurea Compounds. Prognosis. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20639808.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


6. Liu LY, Zhang WZ, Guan J, Tong WC, Cai SX, Shen XB, Hou CC: [Lung cancer in pregnancy: report of two cases and review of literature]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Nov;33(11):844-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in pregnancy: report of two cases and review of literature].
  • OBJECTIVE: to raise awareness about lung cancer in pregnancy.
  • METHODS: the clinical presentations, diagnosis and treatment of 2 cases of lung cancer in pregnancy were reported, and related literatures were reviewed.
  • Biopsy of the right-supraclavicular lymph node was performed simultaneously, and histopathological examination showed metastatic large cell lung cancer.
  • PET showed right lung cancer with metastases to the pericardium, right pleura, liver and pelvic cavity.
  • Bronchoscopic biopsy showed small-cell lung cancer.
  • CONCLUSIONS: lung cancer in pregnancy is a rare condition with poor prognosis.
  • [MeSH-major] Lung Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21211373.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


7. Hasegawa S, Suda T, Negi K, Hattori Y: Lung large cell carcinoma producing granulocyte-colony-stimulating factor. Ann Thorac Surg; 2007 Jan;83(1):308-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung large cell carcinoma producing granulocyte-colony-stimulating factor.
  • In recent years, tumors producing granulocyte-colony-stimulating factor have been reported in an increasing number of patients, the majority of which have lung cancer.
  • We experience a case of lung carcinoma producing granulocyte-colony-stimulating factor treated by resection and chemotherapy.
  • He remains well 2 years and 10 months after surgery, with no recurrence of the carcinoma.
  • [MeSH-major] Carcinoma, Large Cell / metabolism. Granulocyte Colony-Stimulating Factor / biosynthesis. Lung Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184692.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


8. Sanada H, Hayashi A, Tomimitsu S, Ikeda K, Nakanishi K, Hiyama J, Hidaka D, Sawamoto R, Miyagawa Y, Misumi Y, Fujii A, Nakatsubo S, Tsuru M, Omagari J, Koshizuka H: [Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2012-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Estimation of preoperative induction chemoradiotherapy effectiveness for non small-cell lung cancer].
  • We have performed the clinical evaluations of preoperative induction chemoradiotherapy (CRTx) for 25 patients with non small-cell lung cancer (male: 19, female: 6, mean age: 66.4-year-old).
  • In the histological type of lung cancer, there were 12 patients of adenocarcinoma, 7 of squamous cell carcinoma, 1 of adenosquamous carcinoma, 1 of anaplastic carcinoma, and 4 of large cell carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037308.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Lv H, Yan H, Wang M, Li Y, Wan H, Liu H, Wu H, Zhou Q: [Methylation profile difference in human high-metastatic large cell lung cancer cell line L9981 and low-metastatic large cell lung cancer line NL9980]. Zhongguo Fei Ai Za Zhi; 2010 Aug;13(8):763-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Methylation profile difference in human high-metastatic large cell lung cancer cell line L9981 and low-metastatic large cell lung cancer line NL9980].
  • BACKGROUND AND OBJECTIVE: Invasion and metastasis is one of malignant phenotype of lung cancer and the important cause of the death of lung cancer patients.
  • The aim of this study is to explore the methylation profile difference in different metastatic potential cell lines.
  • METHODS: To compare the DNA methylation profile of two large cell lung cancer cell lines with different metastatic potential by MeIP chip hybridization, hypermethylated and hypomethylated genes of L9981 cell lines were analyzed online in NIH-DAVID, KEGG and MILANO webside.
  • RESULTS: Compared with NL9980 cell line, 735 genes are hypermethylated in L9981, including 656 known genes and 79 unknown genes; 809 gene are hypermethylated in L9981, including 698 known genes and 111 unknown genes; the different genes are involved in cell process, signal transduction, cell communication, cell adhesion, cell motility, and angiogenesis.
  • CONCLUSION: Hypermethylation of suppressor genes and negative regulator of signal transduction and hopomethylation of oncogene and cell adhesion molecules (CAMs) in L9981 may promote metastasis of tumor cells.
  • [MeSH-major] Carcinoma, Large Cell / metabolism. DNA Methylation. Lung Neoplasms / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704814.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


10. Naranjo Gómez JM, Gómez Román JJ: Behaviour and survival of high-grade neuroendocrine carcinomas of the lung. Respir Med; 2010 Dec;104(12):1929-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behaviour and survival of high-grade neuroendocrine carcinomas of the lung.
  • INTRODUCTION: Large-cell neuroendocrine carcinoma is an aggressive variant of large-cell carcinoma of the lung, which has poor survival in most series, resembling that of small-cell lung carcinoma.
  • METHODS: 33 large-cell neuroendocrine carcinomas and 16 peripheral small-cell lung carcinomas were reassessed retrospectively.
  • RESULTS: In large-cell neuroendocrine carcinomas, there were 25 patients with pathologic stage I, 4 with pathologic stage II and 4 with pathologic stage III.
  • In small-cell lung carcinomas, there were 6 patients with pathologic stage I, 3 with pathologic stage II and 7 with pathologic stage III.
  • 12% of large-cell neuroendocrine carcinomas and 62.5% of small-cell lung carcinomas were of advanced disease.
  • CONCLUSION: Large-cell neuroendocrine carcinomas of the lung have poor prognosis even in early stages, with survival rates similar to that of small-cell lung carcinomas.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20810262.001).
  • [ISSN] 1532-3064
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res; 2008 May 1;68(9):3389-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
  • Whereas these agents can elicit dramatic clinical responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.
  • We have established an automated platform for examining the sensitivity to various molecularly targeted inhibitors across a large panel of human tumor-derived cell lines to identify additional genotype-correlated responses that may be clinically relevant.
  • Among the inhibitors tested in a panel of 602 cell lines derived from a variety of human cancers, we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed growth of a small subset of tumor cells.
  • This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and neuroblastomas.
  • ALK is a receptor tyrosine kinase that was first identified as part of a protein fusion derived from a chromosomal translocation detected in the majority of anaplastic large cell lymphoma patients, and has recently been implicated as an oncogene in a small fraction of non-small-cell lung cancers and neuroblastomas.
  • Significantly, sensitivity in these cell lines was well correlated with specific ALK genomic rearrangements, including chromosomal translocations and gene amplification.
  • Moreover, in such cell lines, ALK kinase inhibition can lead to potent suppression of downstream survival signaling and an apoptotic response.
  • These findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clinically responsive to pharmacologic ALK inhibition.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Lymphoma / drug therapy. Neuroblastoma / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / genetics. Pyrimidines / therapeutic use
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzimidazoles / therapeutic use. Cell Line, Tumor. Cytogenetic Analysis. Drug Evaluation, Preclinical. Gene Amplification / physiology. Genomic Instability / drug effects. Humans. Mutation. Protein Kinase Inhibitors / therapeutic use. Pyridones / therapeutic use. Receptor Protein-Tyrosine Kinases. Translocation, Genetic


12. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M, University of Hong Kong Lung Cancer Study Group: The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer; 2009 Apr 15;115(8):1723-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
  • BACKGROUND: The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene resulting from the chromosome inversion inv(2)(p21;p23) recently was identified in nonsmall cell lung cancer (NSCLC).
  • METHODS: EML4-ALK was investigated in 266 resected primary NSCLC, including adenocarcinomas (AD), lymphoepithelioma-like carcinomas, squamous cell carcinomas, mucoepidermoid carcinomas, and adenosquamous carcinomas, by reverse transcriptase-polymerase chain reaction and was verified by sequencing.
  • Immunohistochemistry demonstrated diffuse ALK fusion proteins in the tumor cell cytoplasm.
  • The authors concluded that EML4-ALK may be useful for predicting the potential response to ALK inhibitors as a therapeutic option for patients with lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, ras. Lung Neoplasms / genetics. Oncogene Proteins, Fusion / genetics. Receptor, Epidermal Growth Factor / genetics. Smoking


13. Meyronet D, Massoma P, Thivolet F, Chalabreysse L, Rogemond V, Schlama A, Honnorat J, Thomasset N: Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma. Am J Surg Pathol; 2008 Nov;32(11):1699-708
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma.
  • The diagnosis of high-grade neuroendocrine tumors has strong clinical relevance because it identifies patients at higher risk of an unfavorable outcome who should receive multimodal treatment.
  • However, these tumors can be mistaken for poorly differentiated nonsmall cell carcinoma or carcinoid lung tumors.
  • In fact, no immunohistochemical marker can currently distinguish between histologic lung subtypes.
  • Because the collapsin response mediator protein (CRMP) family is involved in an autoimmune disease associated with small cell lung carcinoma, we explored the relationship between CRMP5 expression and lung tumor behavior.
  • Using World Health Organization morphologic criteria, 123 lung neuroendocrine tumors and 41 randomly selected non-neuroendocrine tumors were classified.
  • CRMP5 protein expression in tumors, metastases, and healthy lung tissue was assessed using immunostaining method.
  • Strong and extensive CRMP5 expression was seen in 98.6% of high-grade neuroendocrine lung tumors, including small cell lung carcinoma and large cell lung neuroendocrine carcinoma, but not in any of the squamous cell carcinomas or lung adenocarcinomas in our series.
  • In contrast, the majority of low-grade neuroendocrine lung tumors were negative for CRMP5 staining, although weak CRMP5 expression was seen in some, with 2 different staining patterns of either scattered positive cells or small foci of positive cells.
  • Our findings point at CRMP5 as a novel marker for routine pathologic evaluation of lung tumors surgical samples in distinguishing between highly aggressive neuroendocrine carcinoma and the other lung cancers.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Neuroendocrine / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Nerve Tissue Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18769332.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DPYSL5 protein, human; 0 / Nerve Tissue Proteins
  •  go-up   go-down


14. Nie Q, Zhu W, Liu L, Fu J, Li D, Li Y, Chen J, Wu Z, Zhou Q: [The variation of intracellular distribution and translocation of the protein kinase C alpha among human lung cancer cell line with different metastasis potential.]. Zhongguo Fei Ai Za Zhi; 2008 Jun 20;11(3):363-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The variation of intracellular distribution and translocation of the protein kinase C alpha among human lung cancer cell line with different metastasis potential.].
  • BACKGROUND: Protein Kinase C (PKC) is one of the key kinases in the cell signal transduction passway.
  • There are more reports about it's ability on cell proliferation, but fewer on invasion and metastasis in the past; and it's mechanisms are unclear.
  • The aim of this study is to analyze the variation of intracellular distribution and translocation of the protein kinase C alpha among human high-metastatic large cell lung cancer cell line with different metastasis potential,in order to investigate the correlation between the lung carcinoma invasion and metastasis and the PKC isoforms.
  • The distribution of PKC alpha in cytosol and plasma membrane and translocation were detected among different metastatic potential human pulmonary carcinoma cells L9981, L9981-pLXSN and L9981-nm23-H1 before and after treatment with PKC inhibitor Calphostin C, by Western blot and LSCM.
  • RESULTS: PKC alpha in L9981 and L9981- pLXSN was mainly expressed on membrane, which was remarkably higher than those in L9981-nm23-H1 cell line (P =0.001); while expression of PKC alpha in cytoslol in L9981 and L9981-pLXSN cell lines, was lower than those in L9981-nm23-H1 cell line (P <0.001).
  • The expression of PKC alpha in cytosol in L9981-nm23-H1 cell line was remarkably higher than those in L9981 and L9981-pLXSN cell lines (P <0.001), while expression of PKC alpha in plasma membrane in L9981-nm23-H1 cell line, was significantly lower than those in L9981 and L9981- pLXSN cell lines (P =0.001).
  • PKC alpha is mainly located in nucleus and perinucleus in L9981 and L9981-pLXSN cells, which was in active status, In L9981-nm23-H1 cell line, PKC alpha is mainly located in soluble cytosolic section, which was in inactive status.
  • After treated with PKC inhibitor Calphostin C, the expression of PKC alpha in membrane in L9981, L9981-pLXSN and L9981-nm23-H1 was downregulated, and PKC alpha were observed mainly located in cytosolic site in all the three cell lines, which was mainly in inactive status.
  • CONCLUSIONS: The study suggests that PKC isoforms is closely correlated with human lung cancer invasion and metastasis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731935.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, Aupérin A, Al Ghuzlan A, Travagli JP, Lumbroso J, Baudin E, Schlumberger M: 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging; 2010 Dec;37(12):2277-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.
  • PURPOSE: Our aim was to evaluate in anaplastic thyroid carcinoma (ATC) patients the value of 18F-FDG PET/CT compared with total body computed tomography (CT) using intravenous contrast material for initial staging, prognostic assessment, therapeutic monitoring and follow-up.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Thyroid Carcinoma, Anaplastic. Thyroid Neoplasms / diagnostic imaging

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Feb 1;79(3):564-73 [9028369.001]
  • [Cites] Head Neck. 2007 Aug;29(8):765-72 [17274052.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Langenbecks Arch Surg. 2005 Jun;390(3):203-8 [15599758.001]
  • [Cites] Surgery. 1991 Dec;110(6):956-61; discussion 961-3 [1745983.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1107-13 [10720047.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):564-6 [1985750.001]
  • [Cites] World J Surg. 1998 Jul;22(7):725-30 [9606289.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(13):1773-82 [10673991.001]
  • [Cites] Cancer Control. 2005 Oct;12 (4):254-60 [16258498.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Apr;17(2):75-8 [15830567.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):920-5 [16368753.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):260-4 [11373102.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):78-83 [12490766.001]
  • [Cites] Thyroid. 2008 Jul;18(7):713-9 [18630999.001]
  • [Cites] Langenbecks Arch Surg. 1999 Jun;384(3):284-93 [10437618.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):498-505 [16303836.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1330-5 [15739211.001]
  • [Cites] Head Neck. 2007 Nov;29(11):986-95 [17563906.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):48-56 [18484584.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2335-42 [11413523.001]
  • [Cites] Curr Oncol Rep. 2007 Mar;9(2):152-8 [17288883.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1385-91 [17512192.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Clin Nucl Med. 2007 Jan;32(1):13-5 [17179796.001]
  • [Cites] J Laryngol Otol. 2005 Aug;119(8):585-91 [16102210.001]
  • [Cites] Thyroid. 1998 Aug;8(8):715-26 [9737368.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):112-21 [17237838.001]
  • [Cites] Stat Med. 1998 Jul 15;17 (13):1495-507 [9695194.001]
  • [Cites] Clin Positron Imaging. 1999 May;2(3):153-158 [14516539.001]
  • [Cites] J Nucl Med. 2009 Jan;50(1):88-99 [19139187.001]
  • [Cites] Thyroid. 2004 Nov;14(11):981-2 [15671780.001]
  • [Cites] Int Surg. 2001 Apr-Jun;86(2):117-21 [11918236.001]
  • [Cites] Clin Nucl Med. 2007 Feb;32(2):145-9 [17242574.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1137-43 [15519785.001]
  • [Cites] Lung Cancer. 2008 Oct;62(1):55-61 [18394750.001]
  • [Cites] Head Neck. 1995 Jan-Feb;17(1):41-7; discussion 47-8 [7883548.001]
  • (PMID = 20694463.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


16. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA: The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer; 2010 Jul;46(10):1773-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biology and treatment of EML4-ALK non-small cell lung cancer.
  • The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs).
  • EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features.
  • This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):983-94 [18281673.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3389-95 [18451166.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1536-9 [18414414.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):4971-6 [18593892.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Br J Cancer. 2008 Jul 22;99(2):245-52 [18594528.001]
  • [Cites] Lung Cancer. 2008 Aug;61(2):163-9 [18242762.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6618-24 [18927303.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 [19064915.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):661-70 [19147828.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):508-15 [19234440.001]
  • [Cites] Cancer. 2009 Apr 15;115(8):1723-33 [19170230.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3143-9 [19383809.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5216-23 [19671850.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4247-53 [19667264.001]
  • [Cites] Mol Cancer Res. 2009 Sep;7(9):1466-76 [19737969.001]
  • [Cites] Carcinogenesis. 2010 Jan;31(1):100-10 [19934210.001]
  • [Cites] Ann Surg Oncol. 2010 Mar;17(3):889-97 [20183914.001]
  • [Cites] Clin Cancer Res. 2010 Mar 1;16(5):1561-71 [20179225.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1386-92 [10555007.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3265-8 [10556217.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1525-30 [11745231.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1642-6 [15753357.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5076-83 [15958551.001]
  • [Cites] Chest. 2005 Jul;128(1):317-21 [16002952.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6816-22 [16203769.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):963-9 [16152581.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1647-53 [16533793.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1309-15 [17001163.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5667-72 [17575133.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • (PMID = 20418096.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA136851-02; United States / NCI NIH HHS / CA / R01 CA136851; United States / NCI NIH HHS / CA / R01 CA136851-02; United States / NCI NIH HHS / CA / R01CA136851
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EML4-ALK fusion protein, human; 0 / Enzyme Inhibitors; 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS195408; NLM/ PMC2888755
  •  go-up   go-down


17. Meng Q, Lux A, Holloschi A, Li J, Hughes JM, Foerg T, McCarthy JE, Heagerty AM, Kioschis P, Hafner M, Garland JM: Identification of Tctex2beta, a novel dynein light chain family member that interacts with different transforming growth factor-beta receptors. J Biol Chem; 2006 Dec 01;281(48):37069-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoglin is a membrane-inserted protein that is preferentially synthesized in angiogenic vascular endothelial and smooth muscle cells.
  • Although endoglin is known to affect cell responses to TGF-beta, its mode of action is largely unknown.
  • We performed yeast two-hybrid screening of a human placental cDNA library and isolated a new endoglin-binding partner, a novel 221-amino acid member of the Tctex1/2 family of cytoplasmic dynein light chains named Tctex2beta, as the founder of a new Tctex1/2 subfamily.
  • Reverse transcription-PCR showed expression of Tctex2beta in a wide range of tissues, including vascular endothelial and smooth muscle cells, placenta, and testis, as well as in several tumor cell lines.
  • High expression levels were found in human umbilical vein endothelial cells and the large cell lung cancer cell line.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Bone Morphogenetic Protein Receptors, Type II / metabolism. COS Cells. Cercopithecus aethiops. Dyneins. Humans. Mice. Mink. Molecular Sequence Data. NIH 3T3 Cells. Phylogeny. Protein Binding. Sequence Homology, Amino Acid. t-Complex Genome Region

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982625.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ132441
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BBS/B/02436; United Kingdom / Medical Research Council / / G0900414
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Drosophila Proteins; 0 / Dynlt1b protein, mouse; 0 / Microtubule-Associated Proteins; 0 / Nuclear Proteins; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type II; EC 3.6.4.2 / Dyneins
  •  go-up   go-down


18. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc; 2008 May;83(5):584-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
  • Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world.
  • In North America, lung cancer has become more predominant among former than current smokers.
  • Yet in some countries, such as China, which has experienced a dramatic increase in the cigarette smoking rate during the past 2 decades, a peak in lung cancer incidence is still expected.
  • Non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States.
  • After the initial diagnosis, accurate staging of non-small cell lung cancer using computed tomography or positron emission tomography is crucial for determining appropriate therapy.
  • However, close to 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis.
  • Chemotherapy is beneficial for patients with metastatic disease, and the administration of concurrent chemotherapy and radiation is indicated for stage III lung cancer.
  • The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors.
  • Key terms used for this search included non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, large cell carcinoma, lung cancer epidemiology, genetics, survivorship, surgery, radiation therapy, chemotherapy, targeted therapy, bevacizumab, erlotinib, and epidermal growth factor receptor.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 1995 Dec;50(12):1267-9 [8553299.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):537-44 [9336129.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1782-8 [9392619.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1037-48 [9506347.001]
  • [Cites] Ann Thorac Surg. 1998 Sep;66(3):886-92; discussion 892-3 [9768946.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):99-105 [10408484.001]
  • [Cites] Radiology. 1999 Sep;212(3):803-9 [10478250.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):75-80 [15598942.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):318-28 [15667949.001]
  • [Cites] BMJ. 2005 Feb 5;330(7486):277 [15681570.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Mar;27(3):384-90; discussion 390 [15740943.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2926-36 [15728229.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3175-85 [15886304.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3227-34 [15886310.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2349-54 [15852407.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):85-94 [15949594.001]
  • [Cites] Cancer Causes Control. 2005 May;16(4):389-97 [15953981.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] J Nutr Biochem. 2005 Jul;16(7):385-97 [15992676.001]
  • [Cites] Chest. 2005 Jul;128(1):452-62 [16002972.001]
  • [Cites] Endoscopy. 2005 Sep;37(9):833-9 [16116534.001]
  • [Cites] Respirology. 2005 Sep;10(4):408-17 [16135162.001]
  • [Cites] Am J Clin Nutr. 2005 Sep;82(3):657-67 [16155281.001]
  • [Cites] Carcinogenesis. 2005 Nov;26(11):1846-55 [16123121.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Mol Aspects Med. 2005 Dec;26(6):459-516 [16309738.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2692-9 [10561343.001]
  • [Cites] N Engl J Med. 2000 Jul 27;343(4):254-61 [10911007.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):971-4 [11269483.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Aug;20(2):378-84 [11463561.001]
  • [Cites] Drugs Today (Barc). 2003 Oct;39(10):775-86 [14668933.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2233-41 [15598785.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):263-8 [15620955.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93 [15632829.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):38-75; quiz 77-80 [11577479.001]
  • [Cites] Chin Med J (Engl). 2000 Jul;113(7):617-20 [11776031.001]
  • [Cites] Ann Thorac Surg. 2002 May;73(5):1545-50; discussion 1550-1 [12022547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):370-8 [12243810.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3456S-3464S [12421870.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):633-7 [18385738.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):638-42 [18385739.001]
  • [Cites] BMJ. 1997 Oct 18;315(7114):980-8 [9365295.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1823-7 [14600545.001]
  • [Cites] Respirology. 2003 Dec;8(4):513-21 [14629658.001]
  • [Cites] Lung Cancer. 2004 Feb;43(2):167-73 [14739037.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Mar;127(3):850-6 [15001916.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1297-301 [15054444.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Ann Intern Med. 2004 May 4;140(9):738-9 [15126258.001]
  • [Cites] Zhonghua Jie He He Hu Xi Za Zhi. 2004 Apr;27(4):237-9 [15144613.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):853-61 [15173269.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Ann Thorac Surg. 2006 Feb;81(2):421-5; discussion 425-6 [16427825.001]
  • [Cites] Curr Pharm Des. 2006;12(5):599-613 [16472151.001]
  • [Cites] Ann Thorac Surg. 2006 Mar;81(3):1013-9; discussion 1019-20 [16488712.001]
  • [Cites] Swiss Med Wkly. 2005 Dec 10;135(47-48):697-702 [16511705.001]
  • [Cites] Chest. 2006 Apr;129(4):1088-97 [16608961.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 May;131(5):1014-20 [16678584.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2158-63 [16682734.001]
  • [Cites] Ann Thorac Surg. 2006 Jul;82(1):4-5 [16798177.001]
  • [Cites] Ann Surg. 2006 Sep;244(3):420-5 [16926568.001]
  • [Cites] Mutat Res. 2006 Sep 28;608(2):157-62 [16843042.001]
  • [Cites] Ann Thorac Surg. 2006 Oct;82(4):1175-9 [16996903.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Jan;31(1):88-94 [17116398.001]
  • [Cites] Mayo Clin Proc. 2008 Mar;83(3):355-67 [18316005.001]
  • [Cites] Curr Med Chem. 2003 Feb;10(3):257-66 [12570712.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):921-6 [12610194.001]
  • [Cites] Radiother Oncol. 2003 Feb;66(2):127-40 [12648784.001]
  • [Cites] Lung Cancer. 2003 May;40(2):181-6 [12711119.001]
  • [Cites] Respirology. 2003 Mar;8(1):17-21 [12856737.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] Hum Genet. 2003 Aug;113(3):238-43 [12802680.001]
  • [Cites] J Surg Res. 2003 Sep;114(1):1-5 [13678691.001]
  • [Cites] Int J Epidemiol. 2003 Oct;32(5):802-8 [14559754.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):209-15; discussion 215 [15223430.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2594-601 [15173214.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1245-51 [15279813.001]
  • [Cites] Am J Hum Genet. 2004 Sep;75(3):460-74 [15272417.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3238-47 [15310767.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6392-403 [15322513.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):451-7 [15382071.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1623-31 [15378503.001]
  • [Cites] Chest. 2004 Oct;126(4):1198-203 [15486383.001]
  • [Cites] Am J Med. 1966 Mar;40(3):360-7 [4160252.001]
  • [Cites] N Y State J Med. 1976 Apr;76(4):560-4 [1063302.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):524-30 [1310160.001]
  • [Cites] J Natl Cancer Inst. 1992 Jan 1;84(1):58 [1310747.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 Dec;106(6):1053-8 [8246538.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):198-205 [7707407.001]
  • [Cites] Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3 [7677489.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Ann Thorac Surg. 1995 Dec;60(6):1573-81; discussion 1581-2 [8787446.001]
  • (PMID = 18452692.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-08; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / K12 CA090628-08
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Tobacco Smoke Pollution; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Number-of-references] 115
  • [Other-IDs] NLM/ NIHMS121782; NLM/ PMC2718421
  •  go-up   go-down


19. Al-Qsous W, Miller ID: Anaplastic transformation in lung metastases of differentiated papillary thyroid carcinoma: an autopsy case report and review of the literature. Ann Diagn Pathol; 2010 Feb;14(1):41-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic transformation in lung metastases of differentiated papillary thyroid carcinoma: an autopsy case report and review of the literature.
  • Anaplastic transformation of papillary thyroid carcinoma is a rare condition and is associated with an aggressive behavior.
  • We report a case of an 83-year-old man who, 10 years after being treated for a conventional papillary thyroid carcinoma, presented with widespread metastases in his lungs.
  • At autopsy, he was found to have extensive metastatic deposits in both lungs, which histologically and immunohistochemically were consistent with papillary thyroid carcinoma.
  • An unusual finding was the presence of solid pleomorphic foci within tumor deposits, consistent with anaplastic transformation.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Papillary / secondary. Cell Transformation, Neoplastic / pathology. Lung Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20123456.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


20. Nie Q, Zhu W, Liu L, Fu J, Li D, Li Y, Chen J, Liu H, Zhou Q: [The mechanism and influence on the biological behavior of human high-metastatic large cell lung cancer cell lines with transfection of nm23-H1 gene.]. Zhongguo Fei Ai Za Zhi; 2008 Jun 20;11(3):349-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The mechanism and influence on the biological behavior of human high-metastatic large cell lung cancer cell lines with transfection of nm23-H1 gene.].
  • The aim of this study is to compare the biological behavior changes among three human high-metastatic large cell lung cancer cell lines which transfected and untransfected nm23-H1 gene, and to study the mechanism of nm23-H1 gene supressing the metastasis.
  • METHODS: Boyden Chamber and MTT method were used to detect the rates of invasion and proliferation among different human pulmonary carcinoma cells of transfected and untransfected nm23-H1 gene; meanwhile The three lung cancer cell lines were treated with PKC inhibitor Calphostin C, and the above measurements were also performed.
  • RESULTS: The ability of invasion and proliferation of L9981 and L9981-PLXSN human high-metastatic large cell lung cancer cells,which lack of nm23-H1gene, was higher than that of L9981-nm23-H1 human high-metastatic large cell line, which transfected with nm23-H1gene (P <0.001).
  • There was no difference beteween L9981 and L9981-PLXSN cell lines (P >0.05).
  • After treated with PKC inhibitor Calphstin C,the invasion and proliferation ability of three lung cancer cell lines were obviously go down (P <0.001), however, the invasion and proliferation ability of L9981-nm23-H1 lung cancer cell line was still lower than those of L9981 and L9981-PLXSN lung cancer cell lines (P <0.001), and there was also no significant difference between two later cell lines (P >0.05).
  • CONCLUSIONS: Our data suggest that nm23-H1 gene can significantly inhibit the cell proliferation and invasion in L9981 lung cancer line.
  • The effect of nm23-H1 might be correlated with downregulation of PKC signal transduction in human high-metastatic large cell lung cancer cell line.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731932.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Liao HT, Chien CH, Chen CH, Wang HP, Huang DF: Recurrent autoimmune inner ear disease (AIED) and polyarteritis nodosa in a patient with large cell lung carcinoma. Clin Rheumatol; 2007 Jun;26(6):1008-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent autoimmune inner ear disease (AIED) and polyarteritis nodosa in a patient with large cell lung carcinoma.
  • Autoimmune inner ear disease (AIED) is a very rare disorder with distinct clinical features and can occur in patients with malignancy or autoimmune diseases.
  • During the period of treatment, three episodes of AIED occurred, and eventually, lung cancer developed.
  • From the time relationship and clinical manifestations of neuropathy and livedo reticularis, the first episode of hearing loss was more likely to be related to vasculitis itself, while the third episode may well have been associated with the development of lung cancer given the dramatic improvement in the clinical condition following treatment of the tumor by excision and cancer chemotherapy.
  • [MeSH-major] Autoimmune Diseases / complications. Carcinoma, Large Cell / complications. Carcinoma, Non-Small-Cell Lung / complications. Labyrinth Diseases / immunology. Lung Neoplasms / complications. Polyarteritis Nodosa / complications


22. Al-Brahim N, Ross C, Carter B, Chorneyko K: The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol; 2005 Apr;9(2):77-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the value of autopsy in determining the primary site of MUO, this study reviewed the Hamilton experience-over the last 20 years-with patients autopsied with clinical diagnosis of MUO.
  • Fifty-three cases of MUO were identified (MUO was defined as a patient with pathological and/or radiological diagnosis of a metastatic tumor for which the primary site of malignancy was unknown).
  • Pathological diagnoses at autopsy were adenocarcinoma (n = 37), small cell carcinoma (n = 6), anaplastic carcinoma (n = 3), and undifferentiated carcinoma (n = 3).
  • Primary tumors were identified in 27 patients (51%), most commonly in the lung (n = 8), large bowel (n = 6), and pancreas (n = 4).
  • Histochemical and immunohistochemical stains were helpful in reaching the diagnosis of a primary tumor in 4 of 27 cases.
  • (1) in this series, autopsy was helpful in establishing the diagnosis of a primary tumor in 51% of the cases, reaffirming the value of postmortem examination in these instances;.
  • (3) the lung and the large bowel were the most frequent sites for primary tumors; and (4) careful gross and histological examinations remain the most important tools in identifying the primary site.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Histocytochemistry / methods. Hospitals, University. Humans. Immunohistochemistry / methods. Intestinal Neoplasms / pathology. Intestine, Large. Lung Neoplasms / pathology. Male. Middle Aged. Pancreatic Neoplasms / pathology. Retrospective Studies. Staining and Labeling. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806513.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Fukazawa T, Maeda Y, Durbin ML, Nakai T, Matsuoka J, Tanaka H, Naomoto Y, Tanaka N: Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system. Mol Cancer Ther; 2007 Jan;6(1):244-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system.
  • Gene therapy is one of the approaches used to treat lung cancer.
  • The benefit of cancer gene therapy is that different types of tumors can be selectively targeted by tumor-specific expression of therapeutic genes that include an apoptosis gene to destroy the tumor.
  • Previously, we described a promoter (TTS promoter) that we designed that is specifically targeted to lung cancer cells but not to other types of cancer or normal cells including stem cells.
  • In this pursuit, we further characterize the specificity of the TTS promoter in four types of lung cancer cells (squamous cell lung carcinoma, pulmonary adenocarcinoma, small-cell lung carcinoma, large-cell lung carcinoma).
  • The TTS promoter is highly active only in pulmonary adenocarcinoma cells but not in the other three types of lung cancer cells.
  • The TTS/Bax selectively causes BAX expression and cell death in pulmonary adenocarcinoma but not in other cells.
  • Cell death caused by the BAX expression was also observed in pulmonary adenocarcinoma that is resistant to the anticancer drug gefitinib (epidermal growth factor receptor tyrosine kinase inhibitor).
  • BAX expression and cell death can be suppressed by dexamethasone (a glucocorticoid) treatment through negative glucocorticoid elements in the TTS promoter.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / therapy. Genetic Therapy / methods. Lung Neoplasms / genetics. Lung Neoplasms / therapy. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adenoviridae. Animals. Cell Death / drug effects. Cell Line, Tumor. DNA-Binding Proteins / genetics. Dexamethasone / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Glucocorticoids / pharmacology. Humans. Mice. Organ Specificity. Pulmonary Surfactant-Associated Protein A / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Stem Cells / drug effects. Transcription, Genetic / drug effects. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237283.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Glucocorticoids; 0 / Pulmonary Surfactant-Associated Protein A; 0 / RNA, Messenger; 0 / SFTPA1 protein, human; 0 / TTF1 protein, human; 0 / bcl-2-Associated X Protein; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


24. Che G, Chen J, Liu L, Wang Y, Li L, Qin Y, Zhou Q: Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981. Neoplasma; 2006;53(6):530-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981.
  • In this report, we transfected nm23-H1 cDNA into L9981, a human large cell lung cancer cell line with nm23 negative expression, and made a stable transfectant.
  • L9981-nm23-H1 cells exhibited lower cells proliferation rate, more G0/G1 phase growth and an increase in apoptosis with a dramatic decreased in the tumor cells ability to metastasize.
  • L9981-nm23-H1 cells also demonstrated a significantly reduced lymph node and pulmonary metastatic capacity in vivo when injected into the nude mice.
  • Furthermore, we used DNA microarray analysis to explore the change in expression of the metastasis-related genes in L9981-nm23-H1 cells.
  • These results demonstrated that nm23-H1 can suppress the mobility and metastatic capacity of cancer cells and the molecular mechanism by which nm23-H1 suppresses tumor metastasis may be via increasing the expression of metastasis-related genes such as beta-Catenin, E-Cadherin and TIMP-1 and decreasing the expression of MMP-2, CD44V6 and VEGF.
  • [MeSH-major] Adenocarcinoma / secondary. Antigens, CD44 / metabolism. Cadherins / metabolism. Carcinoma, Non-Small-Cell Lung / therapy. Glycoproteins / metabolism. Matrix Metalloproteinase 2 / metabolism. Nucleoside-Diphosphate Kinase / genetics. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Vascular Endothelial Growth Factor A / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor. Blotting, Western. Cell Proliferation. Gene Expression Profiling. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Male. Mice. Mice, Inbred BALB C. Mice, Nude. NM23 Nucleoside Diphosphate Kinases. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17167724.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Cadherins; 0 / Glycoproteins; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / beta Catenin; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nme1 protein, mouse; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


25. Tambo Y, Kasahara K, Fujimura M, Tamori S, Araya T, Sone T, Nakao S: [A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time]. Gan To Kagaku Ryoho; 2007 Feb;34(2):217-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
  • Chest X-ray revealed a lung mass shadow in the lower left lung field.
  • We diagnosed it as an advanced large cell carcinoma after conducting transbronchial lung biopsy and neck lymphnode biopsy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Lung Neoplasms / drug therapy. Lymph Nodes / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301530.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


26. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell; 2007 Dec 14;131(6):1190-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
  • Despite the success of tyrosine kinase-based cancer therapeutics, for most solid tumors the tyrosine kinases that drive disease remain unknown, limiting our ability to identify drug targets and predict response.
  • Here we present the first large-scale survey of tyrosine kinase activity in lung cancer.
  • Using a phosphoproteomic approach, we characterize tyrosine kinase signaling across 41 non-small cell lung cancer (NSCLC) cell lines and over 150 NSCLC tumors.
  • By focusing on activated cell circuitry, the approach outlined here provides insight into cancer biology not available at the chromosomal and transcriptional levels and can be applied broadly across all human cancers.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Phosphotyrosine / metabolism. Protein-Tyrosine Kinases / metabolism. Signal Transduction / genetics
  • [MeSH-minor] Cell Line, Tumor. Enzyme Activation. Gene Fusion. Humans. Models, Biological. Molecular Sequence Data. Phosphorylation. Receptor Protein-Tyrosine Kinases. Receptor, Platelet-Derived Growth Factor alpha / metabolism


27. Liu Y, Zhang L, Han X, Zhou T: [A case report and literature review of small intestinal metastasis of large cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2010 Jun;13(6):655-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report and literature review of small intestinal metastasis of large cell lung cancer].
  • [MeSH-major] Carcinoma, Large Cell / secondary. Intestinal Neoplasms / secondary. Intestine, Small / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20681458.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 20
  •  go-up   go-down


28. Kawada K, Kitagawa K, Kamei S, Inada M, Mitsuma A, Sawaki M, Kikumori T, Fujimoto Y, Arima H, Imai T, Ando Y: The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Jpn J Clin Oncol; 2010 Jun;40(6):596-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility study of docetaxel in patients with anaplastic thyroid cancer.
  • There is no established chemotherapy for anaplastic thyroid cancer.
  • We conducted a prospective feasibility study at a single center to explore the antitumor activity of docetaxel against anaplastic thyroid cancer.
  • Docetaxel was administered intravenously at a dose of 60 mg/m(2) over the course of 1 h every 3 weeks in patients with anaplastic thyroid cancer who had received no prior chemotherapy.
  • A total of seven patients with anaplastic thyroid cancer were enrolled over the course of 30 months and received docetaxel.
  • Docetaxel could be an effective drug for the treatment of anaplastic thyroid cancer, with tolerable toxicity.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma / drug therapy. Taxoids / administration & dosage. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Aged. Disease Progression. Feasibility Studies. Female. Humans. Infusions, Intravenous. Lung Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20200039.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


29. Trial watch: success for crizotinib in ALK-driven cancer. Nat Rev Drug Discov; 2010 Dec;9(12):908
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trial watch: success for crizotinib in ALK-driven cancer.
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / enzymology. Humans. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Large-Cell, Anaplastic / enzymology. Receptor Protein-Tyrosine Kinases

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119722.001).
  • [ISSN] 1474-1784
  • [Journal-full-title] Nature reviews. Drug discovery
  • [ISO-abbreviation] Nat Rev Drug Discov
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Pyrazoles; 0 / Pyridines; 53AH36668S / crizotinib; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


30. Su CC, Yang JS, Lu CC, Chiang JH, Wu CL, Lin JJ, Lai KC, Hsia TC, Lu HF, Fan MJ, Chung JG: Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. Phytother Res; 2010 Feb;24(2):189-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model.
  • Curcumin can decrease viable cells through the induction of apoptosis in human lung cancer NCI-H460 cells in vitro.
  • However, there are no reports that curcumin can inhibit cancer cells in vivo.
  • In this study, NCI-H460 lung tumour cells were implanted directly into nude mice and divided randomly into four groups to be treated with vehicle, curcumin (30 mg/kg of body weight), curcumin (45 mg/kg of body weight) and doxorubicin (8 mg/kg of body weight).
  • ), with treatment starting 4 weeks after inoculation with the NCI-H460 cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Carcinoma, Large Cell / drug therapy. Curcumin / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Doxorubicin / pharmacology. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CURCUMIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 John Wiley & Sons, Ltd.
  • (PMID = 20077433.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 80168379AG / Doxorubicin; IT942ZTH98 / Curcumin
  •  go-up   go-down


31. Otera H, Ikeda F, Nakagawa S, Kono Y, Sakurai T, Tada K, Hashimoto K, Ikeda A: Intussusception of small intestine due to metastasis of large cell carcinoma of the lung with a rhabdoid phenotype. Eur Respir Rev; 2010 Sep;19(117):248-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intussusception of small intestine due to metastasis of large cell carcinoma of the lung with a rhabdoid phenotype.
  • Large cell carcinoma of the lung with a rhabdoid phenotype is a rare type of lung cancer, and does not commonly metastasize to the small intestine.
  • Herein we describe a 63-yr-old Japanese male with ileus resulting from small intestinal metastasis from lung cancer.
  • [MeSH-major] Carcinoma, Large Cell / complications. Carcinoma, Large Cell / secondary. Intussusception / etiology. Intussusception / pathology. Lung Neoplasms / complications. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20956201.001).
  • [ISSN] 1600-0617
  • [Journal-full-title] European respiratory review : an official journal of the European Respiratory Society
  • [ISO-abbreviation] Eur Respir Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


32. den Bakker MA, Willemsen S, Grünberg K, Noorduijn LA, van Oosterhout MF, van Suylen RJ, Timens W, Vrugt B, Wiersma-van Tilburg A, Thunnissen FB: Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology; 2010 Feb;56(3):356-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability.
  • AIMS: To test the hypothesis that the published morphological criteria permit reliable segregation of small cell carcinoma of the lung (SCLC) and large cell neuroendocrine carcinoma (LCNEC) cases by determining the interobserver variation.
  • METHODS AND RESULTS: One hundred and seventy cases of SCLC, LCNEC and cases diagnosed as neuroendocrine lung carcinoma before LCNEC had been established as a diagnostic category were retrieved from the archives of the assessor's institutes.
  • Unanimity of diagnosis was achieved for only 20 cases; a majority diagnosis was reached for 115 cases.
  • In 35 cases no consensus diagnosis could be reached.
  • [MeSH-major] Carcinoma, Large Cell / epidemiology. Carcinoma, Neuroendocrine / epidemiology. Lung Neoplasms / epidemiology. Small Cell Lung Carcinoma / epidemiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459535.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Brahmbhatt R, Dorsogna L, Cooke P: Primary lung cancer involving mediastinum and mimicking left atrial myxoma: a case report and review of literature. Heart Lung Circ; 2005 Mar;14(1):48-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lung cancer involving mediastinum and mimicking left atrial myxoma: a case report and review of literature.
  • We report a case of primary large cell carcinoma of the lung invading the heart and mimicking a left atrial myxoma.
  • This case highlights the problems we face in diagnosis and management of a very unusual presentation of poorly differentiated primary large ('non-small') cell lung cancer with extension into the left atrium.
  • It is important to have a high index of suspicion for a primary lung malignancy in chronic heavy smokers with none to minimal respiratory symptoms for early diagnosis and full staging procedures, as some of these tumours may be suitable for lung resection.
  • [MeSH-major] Carcinoma, Large Cell / diagnosis. Heart Atria. Heart Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Myxoma / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352252.001).
  • [ISSN] 1443-9506
  • [Journal-full-title] Heart, lung & circulation
  • [ISO-abbreviation] Heart Lung Circ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


34. Yasuda M, Mizukami M, Hanagiri T, Shigematsu Y, Fukuyama T, Nagata Y, So T, Ichiki Y, Sugaya M, Takenoyama M, Sugio K, Yasumoto K: Antigens recognized by IgG derived from tumor-infiltrating B lymphocytes in human lung cancer. Anticancer Res; 2006 Sep-Oct;26(5A):3607-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigens recognized by IgG derived from tumor-infiltrating B lymphocytes in human lung cancer.
  • BACKGROUND: Lung cancer tissues are often infiltrated by B lymphocytes, but it is not clear whether these infiltrations represent tumor-specific immune response or a nonspecific reaction.
  • MATERIALS AND METHODS: The serological analysis of recombinant cDNA expression libraries (SEREX) were previously modified using a severe combined immunodeficient (SCID) mice model engrafted with fresh human lung cancer.
  • Here, a panel of antigens recognized by tumor-infiltrating B lymphocytes (TIB) in human lung cancer were characterized.
  • RESULTS: The modified SEREX analysis identified 22 distinct antigens in a large cell carcinoma of the lung.
  • CONCLUSION: The results of this study indicate that the humoral immune response of TIB in lung cancer patients can be detected in the xenotransplanted SCID mouse model and our modification shows high sensitivity and specificity for identification of tumor antigens.
  • [MeSH-major] Antigens, Neoplasm / immunology. B-Lymphocytes / immunology. Lung Neoplasms / immunology. Lymphocytes, Tumor-Infiltrating / immunology
  • [MeSH-minor] Animals. Antibodies, Neoplasm / immunology. Antibodies, Neoplasm / metabolism. Carcinoma, Large Cell / immunology. Carcinoma, Large Cell / metabolism. Female. Flow Cytometry / methods. Humans. Immunoglobulin G / biosynthesis. Immunoglobulin G / metabolism. Mice. Mice, SCID. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094490.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G
  •  go-up   go-down


35. Machida Y, Lijima M, Nakamura K, Ota S, Hattori N, Mizuno Y: [A 60-year-old man with intention tremor as an initial symptom followed by cerebellar ataxia, peripheral neuropathy and dementia]. No To Shinkei; 2005 Aug;57(8):710-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On neurologic examination, he showed Gottron sign and fine crackle in both lungs.
  • An anaplastic carcinoma was found in his jejunum.
  • Other diagnosis entertained included MERRF, GSS, Ramsay Hunt syndrome, subacute combined degeneration, spinocerebellar degeneration.
  • Post-mortem examination revealed poorly differentiated carcinoma in the small intestine.
  • Neuronal cell loss was observed in the Purkinje cell and granular cell layer in the cerebellum.
  • The neuropathologist concluded that neuropathological diagnosis was a spinocerebellar ataxia with neuropathological similarities to Friedreich ataxia.
  • [MeSH-major] Dementia / complications. Dementia / diagnosis. Paraneoplastic Syndromes / complications. Paraneoplastic Syndromes / diagnosis. Spinocerebellar Ataxias / complications. Spinocerebellar Ataxias / diagnosis. Tremor / etiology
  • [MeSH-minor] Aged. Biomarkers / analysis. Brain / pathology. Carcinoma / complications. Carcinoma / diagnosis. Diagnosis, Differential. Fatal Outcome. Humans. Intestinal Neoplasms / complications. Intestinal Neoplasms / diagnosis. Intestine, Small. Lung Diseases, Interstitial / complications. Lung Diseases, Interstitial / diagnosis. Magnetic Resonance Imaging. Male. Muscle, Skeletal / pathology. Receptors, Interleukin-2 / analysis. Tomography, X-Ray Computed


36. Oshita H, Itai J, Omori K, Okamoto N, Awaya Y: [Pulmonary embolism in a patient with large cell lung carcinoma during chemotherapy-case report]. Gan To Kagaku Ryoho; 2009 Jan;36(1):105-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary embolism in a patient with large cell lung carcinoma during chemotherapy-case report].
  • The patient, a 64-year-old woman, was diagnosed as having large cell carcinoma(stageIV)eighteen months ago.
  • Insertion of a vena cava filter and continuation of anticoagulant therapy were performed to prevent recurrence of PE.
  • Thrombosis is a frequent complication in cancer patients and represents an important cause of morbidity and mortality.
  • Great care should be taken for complications of thrombosis in cancer treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Large Cell / complications. Carcinoma, Large Cell / drug therapy. Lung Neoplasms / complications. Lung Neoplasms / drug therapy. Pulmonary Embolism / complications

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151573.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents
  •  go-up   go-down


37. Tanaka T, Sekimura A, Tanaka H, Tonegawa K, Ogawa K, Haneda H: [Gallbladder metastasis of large cell lung cancer]. Kyobu Geka; 2009 Nov;62(12):1069-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gallbladder metastasis of large cell lung cancer].
  • A man, who received right upper lobectomy of the lung due to stage IIB large cell carcinoma 7 and half years ago, visited our hospital complaining of right upper abdominal pain.
  • Pathological diagnosis was adenosquamous cell carcinoma After 1 year and 4 months later, left adrenal gland tumor was found by CT scan, and the surgery was conducted.
  • Pathologically, it was diagnosed as metastasis from lung cancer.
  • By reevaluation of pathology of the gallbladder, the tumor was found to have similar component of resected lung cancer, suggesting the possibility of the tumor to be metastatic.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Gallbladder Neoplasms / secondary. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894573.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Gao LW, Zhu W, Feng ZH, An N: [Comparative proteomic analysis of human large cell lung cancer cell line with high and low metastasis potentials]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep;39(5):706-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative proteomic analysis of human large cell lung cancer cell line with high and low metastasis potentials].
  • OBJECTIVE: A comparative proteomic analysis on two human large cell lung cancer strains with high metastasis potential (L9981) and low metastasis potential (NL9980) were conducted.
  • METHODS: The total proteins of the two cell lines were separated by immobilized pH gradient (IPG )-based two-dimensional gel electrophoresis.
  • The differential expression proteins of the two cell lines were analyzed using image analysis software.
  • MS and biological informatics study found that the expressions of heat shock 70 kD protein 9B precursor, MTHSP75 and glutathione synthetas incerased in L9981 cells.
  • However, a variant of P47 protein, immunoglobulin heavy chain variable region, enolasel, heat shock protein and eukaryotic translation initiation fact 3 were down-regulated in L9981 cells.
  • Pyruvate kinase (PK) was only expressed in L9981 cells while WD-40 repeat protein was only expressed in NL9980 cells.
  • CONCLUSIONS: The metastatic lung cancer cell lines display different protein profiles compared to the non metastatic lung cancer cell lines.
  • The identified proteins are likely to be associated with tumor metastasis, 4hich could serve as a basis for searching potential prognosis markers of lung cancer and elucidating the mechanisms of the metastasis of lung cancer.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Lung Neoplasms / pathology. Neoplasm Metastasis / pathology. Proteomics / methods
  • [MeSH-minor] Humans. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024295.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


39. Pratz KW, Ma C, Aubry MC, Vrtiska TJ, Erlichman C: Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome. Mayo Clin Proc; 2005 Jan;80(1):116-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome.
  • Verner-Morrison syndrome, characterized by diarrhea, hypokalemia, and hypochlorhydria, is caused most commonly by vasoactive intestinal polypeptide-secreting islet cell tumors of the pancreas.
  • Verner-Morrison syndrome has not been described as a paraneoplastic syndrome in non-small cell lung cancer.
  • We describe a 38-year-old man with metastatic non-small cell lung cancer of large cell carcinoma with neuroendocrine differentiation who presented with bone metastasis and intractable secretory diarrhea that was unresponsive to pharmacological treatment, including octreotide.
  • To our knowledge, this is the first published case of large cell carcinoma with neuroendocrine differentiation associated with treatment-responsive paraneoplastic Verner-Morrison syndrome.
  • [MeSH-major] Calcitonin / secretion. Carcinoma, Large Cell / secretion. Lung Neoplasms / secretion. Pancreatic Neoplasms / etiology. Paraneoplastic Endocrine Syndromes / etiology. Vasoactive Intestinal Peptide / metabolism. Vipoma / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667039.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide; 9007-12-9 / Calcitonin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


41. Sampson JB, Smith SM, Smith AG, Singleton JR, Chin S, Pestronk A, Flanigan KM: Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord; 2007 May;17(5):404-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A third case represents the first association of anti-signal recognition particle (anti-SRP) syndrome with large-cell lung cancer.
  • These cases highlight the role of histopathologic diagnosis in directing the treatment of paraneoplastic myopathy, and the role for IVIG in treatment of the syndrome.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336069.001).
  • [ISSN] 0960-8966
  • [Journal-full-title] Neuromuscular disorders : NMD
  • [ISO-abbreviation] Neuromuscul. Disord.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Complement Membrane Attack Complex; 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


42. Wiles AP, Lomas DJ, Davies J, Save V, Cameron EA: An unusual cause of anaemia. Anaplastic carcinoma. Gut; 2010 Oct;59(10):1339, 1388
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of anaemia. Anaplastic carcinoma.
  • [MeSH-major] Anemia, Iron-Deficiency / etiology. Carcinoma / secondary. Intestinal Neoplasms / secondary. Intestine, Small
  • [MeSH-minor] Heart Transplantation. Humans. Lung Neoplasms. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20542863.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Schmid I, Fliegner M: [Digital ischemia of a patient with undifferentiated large cell lung cancer]. Internist (Berl); 2008 Mar;49(3):346-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Digital ischemia of a patient with undifferentiated large cell lung cancer].
  • [Transliterated title] Digitale Ischämien bei einer Patientin mit grosszelligem Lungenkarzinom.
  • A Raynaud's phenomenon with acral ischemia till necrosis is a rare form of a paraneoplasia.
  • We report about a woman with a metastatic lung cancer, who was admitted because of pain in her left hand with necrosis of the fingertips and of the fifth right toe.
  • The course of a paraneoplastic syndrome is often determined by the underlying malignoma and if the antineoplastic treatment is ineffective, the chances to treat the paraneoplasia may be limited.
  • [MeSH-major] Carcinoma, Large Cell / complications. Carcinoma, Large Cell / diagnosis. Lung Neoplasms / diagnosis. Paraneoplastic Syndromes / diagnosis. Raynaud Disease / diagnosis. Raynaud Disease / etiology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Raynaud's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiologe. 1996 Sep;36(9):692-9 [8999444.001]
  • [Cites] Clin Dermatol. 1993 Jan-Mar;11(1):11-3 [8339184.001]
  • [Cites] Am J Med. 1995 Dec;99(6):662-71 [7503090.001]
  • [Cites] Br J Dermatol. 1996 Dec;135(6):995-8 [8977727.001]
  • [Cites] Am J Med. 1992 May;92(5):571-2 [1580306.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):47-52 [12077580.001]
  • [Cites] Scand J Rheumatol. 2004;33(4):253-6 [15370722.001]
  • [Cites] Curr Opin Rheumatol. 1992 Feb;4(1):90-3 [1543670.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Sep;6(5):331-5 [12448236.001]
  • [Cites] Dtsch Med Wochenschr. 2006 May 26;131(21):1223-7 [16721713.001]
  • [Cites] Dtsch Med Wochenschr. 1994 Aug 26;119(34-35):1162-6 [8076504.001]
  • (PMID = 18214409.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Zhong D, Guo L, de Aguirre I, Liu X, Lamb N, Sun SY, Gal AA, Vertino PM, Zhou W: LKB1 mutation in large cell carcinoma of the lung. Lung Cancer; 2006 Sep;53(3):285-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LKB1 mutation in large cell carcinoma of the lung.
  • Germline inactivation of LKB1 is responsible for Peutz-Jeghers syndrome, an autosomal dominant disorder characterized by benign hamartomas of the GI tract and an increased predisposition to certain cancers, including lung.
  • Acquired mutations in LKB1 are rarely observed in most sporadic tumor types except for adenocarcinomas of the lung where up to 50% harbor inactivating mutations.
  • In this study, we focused on LKB1 mutations in lung cancer cell lines originating from large cell carcinomas.
  • We identified a novel 1.5kb interstitial deletion within LKB1 gene in H157 cancer cells.
  • The truncated transcript was expressed at relatively low levels, and the truncated LKB1 protein was virtually undetectable in this cell line.
  • Phosphorylation of AMPK-alpha was attenuated in H157 cells treated with 2-deoxyglucose, and could be rescued by expression of an exogenous GFP-LKB1 fusion protein.
  • Of the four cell lines and six primary tumors of large cell lung carcinoma origin that have been evaluated in this and other studies, LKB1 mutations have been found in three cases.
  • These results suggest that, in addition to adenocarcinomas, acquired loss of function mutations in LKB1 may also be frequently involved in the pathogenesis of large cell lung carcinomas.
  • [MeSH-major] Carcinoma, Large Cell / metabolism. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Protein-Serine-Threonine Kinases / genetics. Protein-Serine-Threonine Kinases / physiology
  • [MeSH-minor] AMP-Activated Protein Kinases. Alleles. Cell Line, Tumor. DNA, Complementary / metabolism. Gene Deletion. Green Fluorescent Proteins / metabolism. Homozygote. Humans. Loss of Heterozygosity. Multienzyme Complexes / metabolism. Mutation. Phosphorylation. Protein Structure, Tertiary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16822578.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA077337
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Multienzyme Complexes; 147336-22-9 / Green Fluorescent Proteins; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


45. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res; 2009 Aug 15;15(16):5216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
  • PURPOSE: The anaplastic large cell kinase gene (ALK) is rearranged in approximately 5% of lung adenocarcinomas within the Asian population.
  • We evaluated the incidence and the characteristics of ALK-rearranged lung adenocarcinomas within the western population and the optimal diagnostic modality to detect ALK rearrangements in routine clinical practice.
  • EXPERIMENTAL DESIGN: We tested 358 lung adenocarcinomas from three institutions for ALK rearrangements by fluorescent in situ hybridization (FISH) and immunohistochemistry with and without tyramide amplification.
  • RESULTS: We identified 20 (5.6%) lung adenocarcinomas with ALK rearrangements within our cohort of western patients.
  • ALK rearrangement was associated with younger age (P = 0.0002), never smoking (P < 0.0001), advanced clinical stage (P = 0.0001), and a solid histology with signet-ring cells (P < 0.0001).
  • CONCLUSIONS: Lung adenocarcinomas with ALK rearrangements are uncommon in the western population and represent a distinct entity of carcinomas with unique characteristics.
  • For suspected cases, dual diagnostic testing, with FISH and immunohistochemistry, should be considered to accurately identify lung adenocarcinomas with ALK rearrangement.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1515-9 [11717541.001]
  • [Cites] J Surg Oncol. 2002 Jul;80(3):119-20 [12115792.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):459-60 [2156774.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Blood. 1996 Jan 1;87(1):284-91 [8547653.001]
  • [Cites] J Histochem Cytochem. 1996 Dec;44(12):1353-62 [8985127.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):378-83 [10208457.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] Chest. 2005 Jul;128(1):317-21 [16002952.001]
  • [Cites] Semin Respir Crit Care Med. 2005 Jun;26(3):342-52 [16052436.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2498-504 [16353158.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):320-6 [17591931.001]
  • [Cites] J Thorac Oncol. 2007 Jul;2(7):581-2 [17607109.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):29S-55S [17873159.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Lung Cancer. 2006 Apr;52(1):47-52 [16503085.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Jul;4(6):548-82 [16813724.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Ann Thorac Surg. 2007 Jan;83(1):209-14 [17184664.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):810-27 [18391747.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Lung Cancer. 2008 Aug;61(2):163-9 [18242762.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 [19064915.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Apr;48(4):366-80 [19156837.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):508-15 [19234440.001]
  • [Cites] Cancer. 2009 Apr 15;115(8):1723-33 [19170230.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4247-53 [19667264.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):1977-86 [19040416.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1711-21 [10793082.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Histopathology. 2001 Oct;39(4):397-401 [11683941.001]
  • [CommentIn] Clin Cancer Res. 2015 Dec 1;21(23):5185-7 [26626570.001]
  • [ErratumIn] Clin Cancer Res. 2009 Nov 15;15(22):7110
  • (PMID = 19671850.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA136851-02; United States / PHS HHS / / R01-135257; United States / PHS HHS / / R01-136851; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / R01 CA136851-02; United States / NCI NIH HHS / CA / R01 CA136851; United States / NCI NIH HHS / CA / 2P50 CA090578-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS198972; NLM/ PMC2865649
  •  go-up   go-down


46. Malki AM, Gentry J, Evans SC: Differential effect of selected methylxanthine derivatives on radiosensitization of lung carcinoma cells. Exp Oncol; 2006 Mar;28(1):16-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential effect of selected methylxanthine derivatives on radiosensitization of lung carcinoma cells.
  • AIM: Using caffeine as a reference derivative, this study was performed to investigate how other methylxanthine derivatives, theophylline, 3-isobutyl-methylxanthine and 1,3-dipropyl-7-methylxanthine, sensitize cells to radiation by modifying cell cycle checkpoints and inducing the apoptotic response.
  • The effect of the methylxanthine derivatives was studied in response to gamma and ultraviolet radiation in a human large cell lung carcinoma cell line, null for p53, a normal lung epithelial cell line and the large cell lung carcinoma cell line stably transfected with p53.
  • METHODS: Effects of theophylline, 3-isobutyl-methylxanthine and 1,3-dipropyl 7-methylxanthine on cell-radiosensitization in comparison to caffeine tested by clonogenic survival assay, MTT assay, ELISA based apoptotic assay, flow cytometry, caspase-3 activity, TUNEL assay, and western blot analysis.
  • RESULTS: All the derivatives, except 3-isobutyl-methylxanthine, increased tumor cell sensitization to radiation by inducing apoptosis in the p53-null lung cancer cell line.
  • The pattern of cell cycle progression revealed that these derivatives increased the number of cells in G1 phase by abrogating the G2/M checkpoint, directing the cells to apoptose through a p53-independent mechanism.
  • In contrast, 3-isobutyl-methylxanthine was more potent than the other derivatives in radiosensitization of normal lung epithelial cells and the lung carcinoma cells stably transfected with wild-type p53.
  • IBMX increased p53 protein level more than caffeine in lung carcinoma cells stably transfected with wild-type p53.
  • [MeSH-major] Cell Survival / drug effects. Cell Survival / radiation effects. Lung Neoplasms. Radiation-Sensitizing Agents / pharmacology. Xanthines / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / radiation effects. Caffeine / pharmacology. Carcinoma, Large Cell. Cell Line, Tumor. Flow Cytometry. Gamma Rays. Humans. Theophylline / pharmacology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. THEOPHYLLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16614702.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0 / Xanthines; 28109-92-4 / methylxanthine; 3G6A5W338E / Caffeine; C137DTR5RG / Theophylline
  •  go-up   go-down


47. Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Di Cello F, Kowalski J, Elbahloul O, Segal J, Poirier J, Rudin CM, Dhara S, Belton A, Joseph B, Zucker S, Resar LM: Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res; 2009 Nov;7(11):1803-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.
  • Although lung cancer is the leading cause of cancer death worldwide, the precise molecular mechanisms that give rise to lung cancer are incompletely understood.
  • Here, we show that HMGA1 is an important oncogene that drives transformation in undifferentiated, large-cell carcinoma.
  • First, we show that the HMGA1 gene is overexpressed in lung cancer cell lines and primary human lung tumors.
  • Forced overexpression of HMGA1 induces a transformed phenotype with anchorage-independent cell growth in cultured lung cells derived from normal tissue.
  • Conversely, inhibiting HMGA1 expression blocks anchorage-independent cell growth in the H1299 metastatic, undifferentiated, large-cell human lung carcinoma cells.
  • We also show that the matrix metalloproteinase-2 (MMP-2) gene is a downstream target upregulated by HMGA1 in large-cell carcinoma cells.
  • In chromatin immunoprecipitation experiments, HMGA1 binds directly to the MMP-2 promoter in vivo in large-cell lung cancer cells, but not in squamous cell carcinoma cells.
  • In large-cell carcinoma cell lines, there is a significant, positive correlation between HMGA1 and MMP-2 mRNA.
  • Moreover, interfering with MMP-2 expression blocks anchorage-independent cell growth in H1299 large-cell carcinoma cells, indicating that the HMGA1-MMP-2 pathway is required for this transformation phenotype in these cells.
  • Blocking MMP-2 expression also inhibits migration and invasion in the H1299 large-cell carcinoma cells.
  • Our findings suggest an important role for MMP-2 in transformation mediated by HMGA1 in large-cell, undifferentiated lung carcinoma and support the development of strategies to target this pathway in selected tumors.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):585-96 [16254192.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3427-35 [15735694.001]
  • [Cites] J Pathol. 2006 Jun;209(2):206-12 [16521118.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11613-22 [17178855.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):3998-4004 [17483309.001]
  • [Cites] Mol Diagn Ther. 2007;11(3):183-92 [17570740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4256-61 [10759549.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5490-502 [10891489.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4256-61 [10945639.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3944-8 [11051242.001]
  • [Cites] Mol Cell Biol. 2001 Jan;21(2):575-94 [11134344.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6642-50 [11426650.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):63-81 [11602345.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Breast Cancer Res Treat. 2002 Feb;71(3):181-91 [12002338.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):49-52 [12086887.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3371-5 [15150086.001]
  • [Cites] Prostate. 2004 Jul 1;60(2):160-7 [15162382.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] J Natl Cancer Inst. 1977 Jul;59(1):221-6 [327080.001]
  • [Cites] Anticancer Res. 1981;1(6):317-22 [6178358.001]
  • [Cites] FEBS Lett. 1983 Feb 21;152(2):163-7 [6297996.001]
  • [Cites] Nat Rev Cancer. 2007 Dec;7(12):899-910 [18004397.001]
  • [Cites] J Pathol. 2008 Feb;214(3):283-93 [18095256.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10121-7 [19074878.001]
  • [Cites] Nat Genet. 2009 May;41(5):518-20 [19330028.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):98-104 [19820691.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1187-97 [2578876.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2913-23 [2985257.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):798-806 [3940644.001]
  • [Cites] J Biol Chem. 1990 Jul 5;265(19):11077-82 [2162831.001]
  • [Cites] Biochim Biophys Acta. 1990 Jul 30;1049(3):231-43 [2200521.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5481-7 [2386953.001]
  • [Cites] J Biol Chem. 1991 Oct 25;266(30):19945-52 [1939057.001]
  • [Cites] Genomics. 1992 Mar;12(3):503-9 [1559701.001]
  • [Cites] Chest. 1992 Dec;102(6):1808-14 [1446493.001]
  • [Cites] Nucleic Acids Res. 1993 Sep 11;21(18):4259-67 [8414980.001]
  • [Cites] Anticancer Res. 1994 Jan-Feb;14(1B):261-7 [8166465.001]
  • [Cites] J Eukaryot Microbiol. 1996 Jan-Feb;43(1):34-43 [8563708.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1216-22 [9422789.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):623-33 [9816212.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5690-4 [9865724.001]
  • [Cites] Mol Cell Biol. 1999 Aug;19(8):5237-46 [10409715.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8557-62 [15378028.001]
  • [Cites] Pancreas. 2005 Mar;30(2):158-67 [15714138.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • (PMID = 19903768.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA092339-01A1; United States / NCI NIH HHS / CA / R01 CA092339; United States / NCI NIH HHS / CA / P50 CA058184; United States / NCI NIH HHS / CA / CA076130-04; United States / NCI NIH HHS / CA / R29 CA076130; United States / NCI NIH HHS / CA / 1R01CA092339; United States / NCI NIH HHS / CA / R29 CA076130-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 124544-67-8 / HMGA1a Protein; EC 3.4.24.24 / Matrix Metalloproteinase 2
  • [Other-IDs] NLM/ NIHMS149386; NLM/ PMC3069640
  •  go-up   go-down


48. Kalac M, Ostojić S, Gasparov S, Planinc-Peraica A, Dominis M, Jaksić B: [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report]. Lijec Vjesn; 2006 Mar-Apr;128(3-4):76-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
  • Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of extranodal non-Hodgkin lymphoma derived from cytotoxic T-cells, usually manifesting by sinusoidal infiltration of spleen, liver and bone marrow.
  • In 1997 World Health Organization classified malignant lymphomas and placed HSTCL among peripheral T-cell neoplasms.
  • We present a case of a 48-year-old male patient whose initial symptoms were fatigue, weight loss and night sweats, which were followed by splenomegaly and pancytopenia.
  • Upon the completion of the 6th course of therapy he was diagnosed with lung anaplastic microcellular carcinoma and was treated with 3 course of PE therapy (cisplatin, etoposide).
  • [MeSH-major] Carcinoma, Small Cell / pathology. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808095.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


49. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, Zhu M, Zhang X, Wu YL: Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer; 2010;9:188
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
  • BACKGROUND: The anaplastic lymphoma kinase (ALK) gene is frequently involved in translocations that lead to gene fusions in a variety of human malignancies, including lymphoma and lung cancer.
  • Characterization of ALK fusion patterns and their resulting clinicopathological profiles could be of great benefit in better understanding the biology of lung cancer.
  • RESULTS: RACE-coupled PCR sequencing was used to assess ALK fusions in a cohort of 103 non-small cell lung carcinoma (NSCLC) patients.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, ras. Lung Neoplasms / genetics. Mutation. Oncogene Proteins, Fusion / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Cohort Studies. Humans. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3265-8 [10556217.001]
  • [Cites] J Thorac Oncol. 2009 Dec;4(12):1450-4 [20009909.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):781-9 [10702393.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2144-9 [10706887.001]
  • [Cites] Blood. 2000 May 15;95(10):3204-7 [10807789.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):354-62 [12112524.001]
  • [Cites] Mol Diagn. 2003;7(1):27-33 [14529317.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):1038-41 [15297972.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Mutat Res. 2005 Feb 15;570(1):9-15 [15680399.001]
  • [Cites] Exp Cell Res. 2006 Oct 15;312(17):3241-51 [16890222.001]
  • [Cites] Neuroscience. 2007 Feb 23;144(4):1373-82 [17196341.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(4):640-6 [17276053.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):509-20 [17414097.001]
  • [Cites] Pediatr Surg Int. 2007 Jun;23(6):595-9 [17063337.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):4971-6 [18593892.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Lung Cancer. 2008 Aug;61(2):163-9 [18242762.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2480-6 [18785203.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):967-70 [18923523.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6618-24 [18927303.001]
  • [Cites] Cancer Sci. 2008 Dec;99(12):2349-55 [19032370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 [19064915.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):661-70 [19147828.001]
  • [Cites] Mod Pathol. 2009 Apr;22(4):508-15 [19234440.001]
  • [Cites] Cancer. 2009 Apr 15;115(8):1723-33 [19170230.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3143-9 [19383809.001]
  • [Cites] Biochem J. 2009 Jun 15;420(3):345-61 [19459784.001]
  • [Cites] Hum Pathol. 2009 Aug;40(8):1152-8 [19386350.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4232-5 [19667260.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4247-53 [19667264.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):793-8 [10706082.001]
  • (PMID = 20624322.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2908583
  •  go-up   go-down


50. Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ: Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol; 2005 Sep;131(9):585-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
  • Anaplastic thyroid carcinoma (ATC) has a rapidly fatal course in the mostly elderly patients with a median survival after diagnosis of 4-12 months.
  • To further improve therapeutic options in ATC, we evaluated the activity of topotecan, oxaliplatin, vinorelbine, gemcitabine and paclitaxel in comparision to cisplatin and doxorubicin (1 and 96 h drug exposure) alone or in combination in the ATC cell lines SW1736 and 8505C.
  • In conclusion, paclitaxel, gemcitabine and vinorelbine but not topotecan or oxaliplatin appeared to be active in anaplastic thyroid carcinoma based on RAA or growth delay at clinically relevant drug concentrations.
  • [MeSH-minor] Cell Line, Tumor. Cisplatin / pharmacology. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Drug Synergism. Humans. Organoplatinum Compounds / pharmacology. Topotecan / pharmacology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12 [2359136.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1289-90 [11355935.001]
  • [Cites] Anticancer Drugs. 1995 Feb;6(1):64-9 [7756685.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):564-6 [1985750.001]
  • [Cites] Br J Cancer. 1998 Jun;77 Suppl 4:8-11 [9647613.001]
  • [Cites] Rev Invest Clin. 1997 Mar-Apr;49(2):97-103 [9380971.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2087-93 [10815936.001]
  • [Cites] Bull Cancer. 2001 Aug;88 Spec No:S26-34 [11567911.001]
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1083-9 [11061600.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1798-806 [9135025.001]
  • [Cites] Cancer Res. 1989 Aug 1;49(15):4098-102 [2472873.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2516-22 [9661637.001]
  • [Cites] Lung Cancer. 1995 Apr;12 Suppl 1:S155-62 [7551924.001]
  • [Cites] Anticancer Drugs. 1995 Dec;6 Suppl 6:27-32 [8718422.001]
  • [Cites] Eur J Clin Pharmacol. 1992;42(5):545-7 [1607002.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2 Suppl 5):13-22 [9609104.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2127-35 [7901342.001]
  • [Cites] Onkologie. 1991 Feb;14(1):7-12 [2057177.001]
  • [Cites] Oncol Nurs Forum. 1993 Nov-Dec;20(10):1483-9 [7904060.001]
  • [Cites] Radiother Oncol. 1987 Nov;10(3):187-94 [2448847.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3650-3 [8855817.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1769-77 [11297616.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):665-8 [12642691.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1512-8 [11896099.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2155-60 [3902203.001]
  • [Cites] Drugs. 1999 Sep;58(3):533-51 [10493279.001]
  • [Cites] Eur J Cancer. 1990;26(7):834-8 [2145907.001]
  • (PMID = 16021466.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


51. Liu H, Li L, Li XQ, Liu XJ, Zhen YS: Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells. Anticancer Drugs; 2009 Jan;20(1):41-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
  • In this report, the cytotoxic and biochemical activity of LDM and gefitinib on human epidermoid carcinoma A431 cells and human large cell lung cancer H460 cells as a single agent or in combination has been evaluated.
  • In the MTT assay, LDM showed much more potent cytotoxicity than gefitinib to both cell lines.
  • A431 cells with a highly EGFR-expressing level were more sensitive to gefitinib than H460 cells, which expressed EGFR at an intermediate level.
  • LDM plus gefitinib showed potentiation of antiproliferative activity and apoptosis induction, which were associated with downregulation of EGFR signaling pathway and nuclear factor-kappa B expression, and the increase of cleaved poly (adenosine diphosphate-ribose) polymerase in the two cell lines, although to a lesser degree in H460 cells.
  • Combined treatment induced G1 phase arrest similar to that of gefitinib alone in A431 cells and intensified G2/M phase accumulation in H460 cells.
  • The above results indicate that LDM potentiates the effects of gefitinib in both gefitinib sensitive and less sensitive cells in association with enhanced inhibition of EGFR-dependent signaling.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Carcinoma / enzymology. Carcinoma, Squamous Cell / enzymology. Lung Neoplasms / enzymology. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Aminoglycosides / pharmacology. Antibiotics, Antineoplastic / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Synergism. Enediynes / pharmacology. Humans. Phosphorylation. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342999.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Enediynes; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 120177-69-7 / C 1027; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


52. Kim SK, Kim DL, Han HS, Kim WS, Kim SJ, Moon WJ, Oh SY, Hwang TS: Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol; 2008 Jun;17(2):118-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
  • However, 10% to 30% of cases with indeterminate cytology in FNAB need other diagnostic tools to refine diagnosis.
  • METHODS: A total of 103 surgically confirmed patients' FNA slides were recruited and DNA was extracted after atypical cells were scraped from the slides.
  • In detail, 63 (84.0%) of 75 papillary thyroid carcinoma (PTC) samples showed positive BRAF mutation, whereas 3 follicular thyroid carcinomas, 1 anaplastic carcinoma, 1 medullary thyroid carcinoma, and 1 metastatic lung carcinoma did not show BRAF mutation.
  • [MeSH-minor] Biopsy, Fine-Needle. Cell Line, Tumor. DNA, Neoplasm / analysis. Humans. Polymerase Chain Reaction. Predictive Value of Tests


53. Shor S, Helfand SC, Gorman E, Löhr CV: Diagnostic exercise: epithelioid hemangiosarcoma mimicking metastatic prostatic neoplasia in a dog. Vet Pathol; 2009 May;46(3):548-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytologic evaluation of fine needle aspirates from the prostate, testis, and kidney comprised large, clustered or individualized, anaplastic cells that lacked convincing tissue differentiation.
  • Necropsy examination revealed an irregularly enlarged prostate with dark tan to red zones and multiple, discrete, beige to dark red nodules that ranged from 0.5 to 6 cm in diameter in the lung, liver, left kidney, right testis, colon wall, stomach wall, and brain.
  • On histologic examination, discrete nests of anaplastic carcinoma-like tumor cells were found in sections of all affected organs.
  • Results of immunohistochemical examination revealed widespread expression of von Willebrand factor and the absence of cytokeratin in neoplastic cells.
  • The diagnosis was metastatic epithelioid hemangiosarcoma, primary site unknown.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176508.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Ma W, Chen J, Xue X, Wang Z, Liu H, Wang T, Bai Y, Tang SC, Zhou Q: Alteration in gene expression profile and biological behavior in human lung cancer cell line NL9980 by nm23-H1 gene silencing. Biochem Biophys Res Commun; 2008 Jul 4;371(3):425-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration in gene expression profile and biological behavior in human lung cancer cell line NL9980 by nm23-H1 gene silencing.
  • Lung cancer is the leading cause of cancer death in both men and women.
  • Tumor metastasis is an essential aspect of lung cancer progression. nm23-H1 is a metastasis suppressor gene.
  • Here, we compared the gene expression profile of human large cell lung cancer cell line NL9980 by nm23-H1 gene silencing with that of negative control cells to comprehensively investigate nm23-H1-mediated changes in gene expression of NL9980 cells.
  • Furthermore, we confirmed by Western blot that the expression of MMP-1 and -2 were significantly increased while that of cystatin B was dramatically decreased in NL9980-nm23-H1 silencing cells.
  • The NL9980-nm23-H1 silencing cells exhibited significantly more S phase growth and invasive ability.
  • Thus, silencing of nm23-H1 gene caused metastasis-related gene expression changes in lung cancer cells.
  • The knockdown of nm23-H1 expression may change the lung cancer cells to a more invasive phenotype through alteration in the expression of a set of genes.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lung Neoplasms / genetics. Lung Neoplasms / pathology. NM23 Nucleoside Diphosphate Kinases / genetics. NM23 Nucleoside Diphosphate Kinases / physiology
  • [MeSH-minor] Cell Line, Tumor. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. RNA Interference. RNA, Small Interfering / genetics


55. Mano H: Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci; 2008 Dec;99(12):2349-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
  • However, chromosome translocations involving the e26 transformation-specific sequence transcription factor loci have been demonstrated recently in many prostate cancer cases.
  • Furthermore, through a functional screening with retroviral cDNA expression libraries, we have discovered the fusion-type protein tyrosine kinase echinoderm microtubule-associated protein like-4 (EML4)-anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) specimens.
  • EML4-ALK oligomerizes constitutively in cells through the coiled coil domain within the EML4 region, and becomes activated to exert a marked oncogenicity both in vitro and in vivo.
  • Break and fusion points within the EML4 locus may diverge in NSCLC cells to generate various isoforms of EML4-ALK, which may constitute approximately 5% of NSCLC cases, at least in the Asian ethnic group.
  • In the present review I summarize how detection of EML4-ALK cDNA may become a sensitive diagnostic means for NSCLC cases that are positive for the fusion gene, and discuss whether suppression of ALK enzymatic activity could be an effective treatment strategy against this intractable disorder.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Neoplasms / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Carcinoma, Adenosquamous / genetics. Cell Transformation, Neoplastic. Chromosomes, Human, Pair 2. Exons. Gene Rearrangement. Humans. Male. Middle Aged. Models, Genetic. Translocation, Genetic

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032370.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 71
  •  go-up   go-down


56. Bestvater F, Dallner C, Spiess E: The C-terminal subunit of artificially truncated human cathepsin B mediates its nuclear targeting and contributes to cell viability. BMC Cell Biol; 2005;6(1):16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The C-terminal subunit of artificially truncated human cathepsin B mediates its nuclear targeting and contributes to cell viability.
  • Although Delta51CB is supposed to be devoid of the typical CB enzymatic activity, it might play a role in malignancies and trigger cell death/apoptosis independent from the function of the regular enzyme.
  • RESULTS: We investigated such "aberrant" proteins by artificial CB-GFP chimeras covering various sequence parts in respect to their enzymatic activity, their localization in different cell types, and the effects on the cell viability.
  • Unlike the entire full length CB form, the artificial single chain form was not processed and did not reveal typical enzymatic CB activity during transient overexpression in large cell lung carcinoma cells.
  • In contrast, the shorter artificial CB constructs localized in the cytoplasm, inside the cell nucleus, and in the midbodies of dividing cells.
  • Nuclear accumulation of artificially truncated CB variants led to disintegration of nuclei, followed by cell death.
  • CONCLUSION: We propose that cell death associated with CB is not necessarily triggered by its regular enzymatic activity but alternatively by a yet unknown activity profile of truncated CB.
  • Cytoplasmic CB might be able to enter the cell nucleus.
  • The results suggest that besides the N-terminal signal peptide also other CB domains contain patterns which are responsible for a differentiated targeting of the molecule, e.g. to the mitochondria, to the nucleus, or to vesicles.
  • [MeSH-major] Active Transport, Cell Nucleus. Cathepsin B / genetics. Cathepsin B / metabolism
  • [MeSH-minor] Carcinoma, Large Cell / pathology. Cell Line, Tumor. Cell Survival. Cytoplasm / chemistry. Humans. Lung Neoplasms / pathology. Mitochondria / chemistry. Mutagenesis, Site-Directed. Protein Sorting Signals. Protein Subunits. Protein Transport. Signal Transduction. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Photochem Photobiol. 2000 Feb;71(2):196-200 [10687394.001]
  • [Cites] Gene. 1995 Jul 4;159(2):143-9 [7622042.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):604-9 [10766243.001]
  • [Cites] Adv Exp Med Biol. 1996;389:281-94 [8861022.001]
  • [Cites] Br J Cancer. 1997;75(8):1137-43 [9099961.001]
  • [Cites] J Histochem Cytochem. 1997 Jul;45(7):975-83 [9212823.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1714-26 [9352877.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):13236-44 [9582368.001]
  • [Cites] FEBS Lett. 1998 Nov 6;438(3):150-8 [9827536.001]
  • [Cites] Gene. 1998 Oct 9;221(1):35-43 [9852947.001]
  • [Cites] J Clin Invest. 1999 Jan;103(1):137-45 [9884343.001]
  • [Cites] Cell Biochem Biophys. 1999;30(1):71-88 [10099823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):192-7 [15618392.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11973-80 [15657038.001]
  • [Cites] Arthritis Rheum. 2001 Aug;44(8):1819-31 [11508434.001]
  • [Cites] Hepatology. 2004 Jul;40(1):185-94 [15239102.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):41012-7 [15262981.001]
  • [Cites] Biophys J. 1976 Sep;16(9):1055-69 [786399.001]
  • [Cites] Nat Cell Biol. 2000 Jun;2(6):E107-12 [10854340.001]
  • [Cites] J Clin Invest. 2000 Nov;106(9):1127-37 [11067865.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):21-2 [11134173.001]
  • [Cites] Exp Cell Res. 2001 Jan 15;262(2):84-94 [11139332.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 30;1536(1):31-42 [11335102.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):999-1010 [11381085.001]
  • [Cites] Biol Chem. 2001 May;382(5):735-41 [11517926.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11533-8 [11796715.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6286-91 [11959917.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Oct;283(4):G947-56 [12223355.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39499-506 [12185082.001]
  • [Cites] J Microsc. 2002 Nov;208(Pt 2):108-15 [12423261.001]
  • [Cites] EMBO J. 2002 Dec 2;21(23):6527-38 [12456659.001]
  • [Cites] Histochem Cell Biol. 2003 Feb;119(2):93-101 [12610728.001]
  • [Cites] Curr Top Dev Biol. 2003;54:313-41 [12696754.001]
  • [Cites] Biophys J. 2003 May;84(5):3353-63 [12719264.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21295-306 [12663669.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):271-86 [12785001.001]
  • [Cites] J Clin Invest. 2003 Jul;112(2):152-9 [12865404.001]
  • [Cites] Biol Chem. 2003 Jun;384(6):845-54 [12887051.001]
  • [Cites] Cell Death Differ. 2003 Sep;10(9):956-68 [12934070.001]
  • [Cites] EMBO J. 2003 Oct 1;22(19):5313-22 [14517268.001]
  • [Cites] Biochem Soc Symp. 2003;(70):263-76 [14587299.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3719-26 [12893746.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Dec;14(12):1330-9 [14652182.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2881-90 [15077151.001]
  • [Cites] Mol Cell. 2004 Apr 23;14(2):207-19 [15099520.001]
  • [Cites] Dev Cell. 2004 May;6(5):610-1 [15130484.001]
  • [Cites] Biophys J. 2004 Jun;86(6):3473-95 [15189848.001]
  • [Cites] Science. 2004 Jul 2;305(5680):61-6 [15166316.001]
  • [Cites] J Histochem Cytochem. 1981 Mar;29(3A Suppl):440-50 [6972405.001]
  • [Cites] J Biol Chem. 1981 Aug 25;256(16):8536-44 [7263668.001]
  • [Cites] Anat Rec. 1989 Mar;223(3):266-75 [2646985.001]
  • [Cites] DNA Cell Biol. 1993 May;12(4):299-309 [8494608.001]
  • [Cites] J Histochem Cytochem. 1994 Jul;42(7):917-29 [8014475.001]
  • [Cites] Ann Rheum Dis. 1995 Apr;54(4):289-97 [7763107.001]
  • [Cites] DNA Cell Biol. 2000 Feb;19(2):79-91 [10701774.001]
  • (PMID = 15807897.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Sorting Signals; 0 / Protein Subunits; EC 3.4.22.1 / Cathepsin B
  • [Other-IDs] NLM/ PMC1087480
  •  go-up   go-down


57. Liu J, Zhong X, Zhou Q, Gao AC, Wang Y, Zhu W, Ma L, Zhang Z: [Primary experimental results of methylseleninic acid on the proliferation inhibition and apoptotic induction in human high-metastatic large cell lung cancer cell line L9981]. Zhongguo Fei Ai Za Zhi; 2006 Apr 20;9(2):103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary experimental results of methylseleninic acid on the proliferation inhibition and apoptotic induction in human high-metastatic large cell lung cancer cell line L9981].
  • BACKGROUND: It has been proved that selenium has remarkable effects in the prevention of cancer and proliferation inhibition for breast cancer and prostate cancer.
  • Up to now, little is known, however, if methylseleninic acid (MSA) has the anticancer effect on lung cancer or not.
  • The objective of this study is to detect the effect of MSA on proliferation inhibition and apoptotic induction for human high-metastatic large cell lung cancer cell line L9981, and to explore the molecular mechanisms.
  • METHODS: The changes of proliferation, clone formation, apoptotic level and cell cycles were detected in L9981 by trypan blue staining, clone formation suppression test, and flow cytometry before and after treating with different concentration of MSA.
  • RESULTS: (1)The proliferation ability of L9981 was remarkably inhibited at the concentration of 0.5μmol/L of MSA (P < 0.05), and the cells were arrested at G0/G1 phase after treating with the same concentration. (2)Apoptosis of L9981 was remarkably induced by MSA at the concentration of 2.5μmol/L (P < 0.05). (3)The clone formation ability of L9981 was significantly suppressed by MSA at the concentration of 5.0μmol/L (P < 0.05). (4)The expression levels of P53, P21, Fas, FasL and Bax were remarkably up-regulated after treatment with MSA.
  • CONCLUSIONS: (1)MSA can significantly suppress the proliferation and clone formation ability of human high-metastatic large cell lung cancer cell line L9981, and also induce apoptosis of L9981. (2)The anticancer effects of MSA might be related to regulate the expression of cell cycle-related genes and apoptotic-related genes in the human high-metastatic large cell lung cancer line L9981.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21144291.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


58. Marie Y, Carpentier AF, Omuro AM, Sanson M, Thillet J, Hoang-Xuan K, Delattre JY: EGFR tyrosine kinase domain mutations in human gliomas. Neurology; 2005 Apr 26;64(8):1444-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain.
  • In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas.
  • No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib.
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / enzymology. Astrocytoma / genetics. Carcinoma / drug therapy. Carcinoma / enzymology. Carcinoma / genetics. DNA Mutational Analysis. Drug Resistance, Neoplasm / genetics. Genetic Testing. Glioblastoma / drug therapy. Glioblastoma / enzymology. Glioblastoma / genetics. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / enzymology. Oligodendroglioma / genetics. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Protein Structure, Tertiary / genetics. Quinazolines / pharmacology. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851741.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


59. Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA: Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res; 2009 Feb 15;69(4):1536-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.
  • Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of the disease for which new therapeutic options are desperately needed.
  • Previously, we showed that the high-affinity peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, RS5444, inhibits cell proliferation of ATC cells via induction of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) (p21).
  • We show here that up-regulation of RhoB is a critical step in PPARgamma-mediated activation of p21-induced cell stasis.
  • Using multiple independently derived ATC cell lines, we found that treatment with RS5444 leads to the up-regulation of RhoB and subsequent activation of p21, and that silencing of RhoB by RNAi blocks the ability of RS5444 to induce p21 and to inhibit cell proliferation.
  • We further implicate RhoB as a key signaling effector for the growth inhibition of ATC, as treatment with a histone deacetylase inhibitor shown to increase RhoB expression in lung cancer cells caused the up-regulation of RhoB in ATC cells accompanied by increased expression of p21 and inhibition of cell proliferation; this effect occurred even in ATC cells that were unresponsive to RS5444 due to a lack of expression of PPARgamma.

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5492-6 [10554025.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):17-44 [18987168.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):17974-8 [10770919.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1157-64 [11078801.001]
  • [Cites] Semin Cancer Biol. 2000 Dec;10(6):443-52 [11170866.001]
  • [Cites] J Mol Med (Berl). 2001;79(1):30-47 [11327101.001]
  • [Cites] Hepatology. 2001 May;33(5):1087-97 [11343236.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6192-7 [11353846.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):162-8 [11905808.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):9-15 [11918088.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2225-32 [12114424.001]
  • [Cites] Mol Cancer Ther. 2001 Dec;1(2):141-9 [12467231.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):1-9 [12538445.001]
  • [Cites] Cell Cycle. 2002 Nov-Dec;1(6):430-7 [12548020.001]
  • [Cites] Endocrinology. 2003 Sep;144(9):3852-9 [12933658.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6204-13 [13679859.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1136-45 [14647415.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1301-12 [15020670.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2742-50 [15102679.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2865-75 [14976143.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5565-76 [15169915.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):179-84 [8423216.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):6443-53 [7565796.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4689-97 [9671479.001]
  • [Cites] Mol Cell. 1999 Jun;3(6):799-804 [10394368.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5774-85 [15345676.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8389-96 [15548709.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):502-11 [15543229.001]
  • [Cites] J Biol Chem. 2005 May 13;280(19):19243-9 [15713677.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3958-65 [15897598.001]
  • [Cites] Histol Histopathol. 2006 Feb;21(2):213-8 [16329046.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2304-17 [16331265.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2736-47 [16314832.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jun 7;251(1-2):17-32 [16574311.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):1021-35 [16795079.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Oct;58(4):460-70 [16435154.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4463-75 [16777971.001]
  • [Cites] Thyroid. 2006 Dec;16(12):1293-302 [17199440.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Cell Physiol. 2007 Jul;212(1):1-12 [17443682.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23387-401 [17565986.001]
  • [Cites] BMC Cancer. 2007;7:220 [18047684.001]
  • [Cites] Annu Rev Biochem. 2008;77:289-312 [18518822.001]
  • [Cites] Cancer Gene Ther. 2008 Jul;15(7):456-64 [18340357.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1129-38 [10706135.001]
  • (PMID = 19208833.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA015083-34; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / P30 CA015083-34; United States / NCI NIH HHS / CA / P30CA15083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; EC 3.6.5.2 / rhoB GTP-Binding Protein; M17ILL71MC / efatutazone
  • [Other-IDs] NLM/ NIHMS83531; NLM/ PMC2644344
  •  go-up   go-down


60. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR Jr, Moran C, Allen PK, Komaki R: Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):779-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
  • PURPOSE: To retrospectively compare outcomes for patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) treated at our institution with concurrent chemoradiation with or without induction chemotherapy.
  • A planned subgroup analysis showed that induction chemotherapy was associated with a significant overall survival benefit for patients with adenocarcinoma or large-cell carcinoma (5-year rate, 24% vs. 8%; p = 0.003) but not for those with squamous cell carcinoma.
  • A multivariate analysis of patients with adenocarcinoma or large-cell carcinoma confirmed that induction chemotherapy was the most significant factor associated with better overall survival, with a hazard ratio of 0.47 (95% confidence interval, 0.28-0.78; p = 0.003).
  • CONCLUSION: Our retrospective analysis suggests that in combination with concurrent chemoradiation, induction chemotherapy may provide a small but significant survival benefit for patients with unresectable locally advanced adenocarcinoma or large-cell carcinoma of the lung.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / therapy. Drug Therapy / mortality. Lung Neoplasms / mortality. Lung Neoplasms / therapy. Radiotherapy, Adjuvant / mortality. Risk Assessment / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418967.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hu B, Chen J, Liu H, Wu H, Wu Z, Wang Y, Bai Y, Li Y, Zhou Q: [Genome-wide detection of loss of heterozygosity and copy number variation in a human lung large cell carcinoma cell line by affymetrix single-nucleotide polymorphism array 500K.]. Zhongguo Fei Ai Za Zhi; 2008 Jun 20;11(3):327-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genome-wide detection of loss of heterozygosity and copy number variation in a human lung large cell carcinoma cell line by affymetrix single-nucleotide polymorphism array 500K.].
  • BACKGROUND: Loss of heterozygosity (LOH) and Copy number copy number variation (CNV) of DNA sequences is a common feature of cancer genomes, which is thought to be linked to tumorigenesis and progression.
  • High-density singlenucleotide polymorphism (SNP) genotyping array are able to provided a genotype and copy number information with genome-wide coverage, which is suitable for the analysis of complex genetic alterations present in cancer.
  • Thus a human lung large cell carcinoma cell line NL9980 was assayed for the global profile of LOH and CNV.
  • METHODS: Genomic DNA from the cell line was screened for LOH and CNV using Affymetrix GeneChip(R) Human Mapping array 500K Set.
  • The hybridization intensity data of 500 000 SNP loci was analyzed using Affymetrix proprietary software for genotyping and copy number of each locus, and a genome-wide map of LOH and CNV of the cell line was constructed.
  • And it is possible to achieve high performance outcomes using Affymetrix SNP array 500K to interrogate LOH and CNV in lung cancer genome.
  • This advance of highresolution with allelic information should substantially improve the ability to further understanding of the genetic basis of lung cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731928.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Oyama T, Rombel IT, Samli KN, Zhou X, Brown KC: Isolation of multiple cell-binding ligands from different phage displayed-peptide libraries. Biosens Bioelectron; 2006 Apr 15;21(10):1867-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation of multiple cell-binding ligands from different phage displayed-peptide libraries.
  • A technical challenge in the development of biosensor devices for cancer detection and diagnosis is the identification of ligands that recognize cancer cells with high affinity and specificity.
  • Furthermore, it is unlikely that one cell-binding ligand will provide sufficient biological information, thus, multiple ligands for a given cancer type will be needed for confident clinical diagnosis.
  • Biopanning of phage displayed peptide libraries is a route to isolation of specific cell-binding reagents.
  • A potential approach towards isolation of multiple ligands for a single cell type is to pan against the same cell type using different peptide libraries.
  • Here we report the synthesis of a new 20-mer peptide-phage library and its use to select a peptide that binds to the large cell lung carcinoma cell line, H1299.
  • The isolated phage clone binds H1299 cells 80 times better than a control phage and can distinguish between H1299 and normal control cells.
  • The phage clone also binds to the lung pleura epidermoid cell line, Calu-1 but not to all lung carcinoma cell lines.
  • The tetrameric peptide can be used to deliver a fluorescent quantum dot to H1299 cells.
  • Our results imply that cell-based biopanning can isolate cell-binding ligands that may be of utility for cancer diagnosis, and isolation of cell-targeting peptides from different peptide libraries can expand the repertoire of cell-binding reagents.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386888.001).
  • [ISSN] 0956-5663
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106646; United States / NCI NIH HHS / CA / 1 R01 CA 106646-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ligands; 0 / Peptide Library
  •  go-up   go-down


63. Wang T, Xu J, Zhong NS: [Relationship between the acquired multi-drug resistance of human large cell lung cancer cell line NCI-H460 by cisplatin selection and p53 mutation]. Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb;28(2):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between the acquired multi-drug resistance of human large cell lung cancer cell line NCI-H460 by cisplatin selection and p53 mutation].
  • OBJECTIVE: To explore the role of p53 mutation in the development of acquired multi-drug resistance during lung cancer chemotherapy.
  • METHODS: A resistance large cell lung carcinoma cell line (H460/DDP) was established by high dose (50 micromol/L) cisplatin intermittent selection from its parental cell NCI-H460 that had wild type p53 (wtp53).
  • Several multi-drug resistant proteins (MRP) including lung relative protein (LRP), P-gp, MRP, glutathione transferase-pi, topoisomerase II and P53 were checked by immunocytochemistry.
  • The H460/DDP cells were transected with plasmid pShuttle-CMV-wtp53 cDNA and measurement of drug sensitivity was performed after transfection.
  • RESULTS: The resistance index to cisplatin and carboplatin in H460/DDP cell line was 10.21 and 9.98 respectively, and the cell line also exhibited cross-resistance to 5-fluorouracil, etoposide, methotrexate, adriamycin, epirubicin, bleomycin and novantrone, except for taxol.
  • H460/DDP cells transfected with plasmid pShuttle-CMV-wtp53 cDNA reversed partly (53.2%) the resistance to cisplatin/carboplatin, compared to the H460/DDP cells transfected with blank vector.
  • CONCLUSIONS: p53 mutation induced by cisplatin/carboplatin might play an important role in the development of acquired multi-drug resistance of lung cancer chemotherapy. wtp53 substitute therapy during chemotherapy may be an effective method to overcome the acquired drug resistance.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Drug Resistance, Neoplasm / genetics. Lung Neoplasms / pathology. Multidrug Resistance-Associated Proteins / biosynthesis. Mutation. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Cell Line, Tumor. Cisplatin. Drug Resistance, Multiple / genetics. Humans. P-Glycoprotein / biosynthesis. Transfection


64. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T, Date H: Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol; 2010 Mar;17(3):889-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
  • BACKGROUND: A fusion gene between echinoderm microtubule-associated protein-like 4 (EML4) and the anaplastic lymphoma kinase (ALK) has recently been identified in nonsmall-cell lung cancers (NSCLCs).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Mutation / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Aged. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proto-Oncogene Proteins / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, Epidermal Growth Factor / genetics. Receptor, ErbB-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction. ras Proteins / genetics


65. Kelleher FC, McDermott R: The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer; 2010 Sep;46(13):2357-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
  • The anaplastic lymphoma kinase gene (ALK) is a gene on chromosome 2p23 that has expression restricted to the brain, testis and small intestine but is not expressed in normal lymphoid tissue.
  • This gene was originally established as being implicated in the pathogenesis of rare diseases including inflammatory myofibroblastic tumour (IMT) and ALK-positive anaplastic large cell lymphoma, which is a subtype of non-Hodgkin's lymphoma.
  • In 2007, an inversion of chromosome 2 involving ALK and a fusion partner gene in a subset of non-small cell lung cancer was discovered.
  • In 2008, publications emerged implicating ALK in familial and sporadic cases of neuroblastoma, a childhood cancer of the sympatho-adrenal system.
  • This has been described in ALK-positive anaplastic large cell lymphoma in which ALK is fused to NPM (nucleolar protein gene) and in non-small cell lung cancer where ALK is fused to EML4 (Echinoderm microtubule-associated protein 4).
  • Point mutations and amplification of the ALK gene occur in the childhood cancer neuroblastoma.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / therapy. Drug Synergism. Gene Amplification. Humans. Lung Neoplasms / genetics. Lung Neoplasms / therapy. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / therapy. Mutation / genetics. Neuroblastoma / genetics. Neuroblastoma / therapy. Pyrimidines / therapeutic use. Pyrroles / therapeutic use. Receptor Protein-Tyrosine Kinases. Receptor, IGF Type 1 / antagonists & inhibitors

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20451371.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GSK 1838705A; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


66. Martin AC, Friedlander M, Kiernan MC: Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma. J Clin Neurosci; 2006 Jun;13(5):595-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma.
  • A 60-year-old man developed two selective peripheral mononeuropathies of the peroneal and later the radial nerve, shortly after a diagnosis of large-cell lung carcinoma.
  • Subsequent magnetic resonance imaging of the lower limb excluded focal compression or malignant infiltration along the course of the peroneal nerve, and there was no signal change within the nerve, prompting a diagnosis of paraneoplastic mononeuritis multiplex.
  • Neither the patient's large-cell lung carcinoma nor mononeuritis multiplex responded to chemotherapy, and he died within 6 months of the initial diagnosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Paraneoplastic Polyneuropathy / radiography. Peroneal Neuropathies / radiography. Radial Neuropathy / radiography

  • Genetic Alliance. consumer health - Mononeuritis multiplex.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564174.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


67. Willemsen MA, Breedveld GJ, Wouda S, Otten BJ, Yntema JL, Lammens M, de Vries BB: Brain-Thyroid-Lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr; 2005 Jan;164(1):28-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain-Thyroid-Lung syndrome: a patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene.
  • He died from large cell lung carcinoma at the age of 23 years.
  • A de novo heterozygous insertion mutation 859-860insC in the TITF-1 gene was demonstrated.
  • CONCLUSION: TITF-1 gene mutations should be considered in paediatric and adult patients with unexplained (combinations of) chorea, mental retardation, primary hypothyroidism, and chronic lung disease.
  • Introduction of a name for the disorder, e.g.
  • Brain-Thyroid-Lung syndrome, would probably facilitate further recognition.
  • Whether the TITF-1 gene mutation in this patient predisposed to the development of lung cancer remains speculative.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2002 Apr 15;11(8):971-9 [11971878.001]
  • [Cites] J Clin Invest. 2002 Feb;109(4):475-80 [11854319.001]
  • [Cites] Development. 1991 Dec;113(4):1093-104 [1811929.001]
  • [Cites] Mol Carcinog. 2004 Aug;40(4):212-31 [15264213.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Jul 15;166(2):215-35 [12119235.001]
  • [Cites] Respir Res. 2000;1(2):109-15 [11667973.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1317-8 [9565498.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2527-39 [14695413.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9443-8 [10944215.001]
  • [Cites] J Pediatr. 2004 Aug;145(2):190-3 [15289765.001]
  • [Cites] J Clin Invest. 2002 Feb;109(4):469-73 [11854318.001]
  • [Cites] Ann Neurol. 2003 Aug;54(2):244-7 [12891678.001]
  • [Cites] Pediatr Pathol Mol Med. 2001 Sep-Oct;20(5):413-32 [11552740.001]
  • (PMID = 15517377.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


68. Petrović M, Tomić I, Ilić S: [Neuroendocrine differentiation as a survival prognostic factor in advanced non-small cell lung cancer]. Vojnosanit Pregl; 2007 Aug;64(8):525-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine differentiation as a survival prognostic factor in advanced non-small cell lung cancer].
  • BACKGROUND/AIM: Neuroendrocine lung tumors are histologically heterogenous group of cancers with different clinical progression.
  • In non-small cell lung cancer (NSCLC) neuroendocrine differentiation exists in 10-30% of patients.
  • The aim of this study was to determine the frequency and influence of neuroendocrine differentiation on survival of treated patients with advanced non-small cell lung cancer (NSCLC).
  • METHODS: A clinical trial included 158 patients (74% males and 26% females), with the diagnosis of NSCLC, determined by histological verification.
  • RESULTS: A total of 53 patients (34%) had NSCLC with neuroendocrine differentiation, confirmed rather in large cell lung cancer and lung adenocarcinoma (66.7% and 40%, respectively).
  • One year follow-up survival time was longer in the patients with neuron specific enolase and chromogranin A expression lung cancer (p < 0.001).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Chromogranin A / analysis. Lung Neoplasms / mortality. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis


69. Uchida N, Fukino S, Kodama W, Tamai N, Hiroe T, Fukata T: Large-cell carcinoma of the lung with a remarkable preoperative elevation of serum carcinoembryonic antigen level. Gen Thorac Cardiovasc Surg; 2007 May;55(5):217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell carcinoma of the lung with a remarkable preoperative elevation of serum carcinoembryonic antigen level.
  • Carcinoembryonic antigen, a serum tumor marker, is useful for diagnosing cancer and for following the response to therapy in cancer cases.
  • Chest computed tomography revealed a tumor in the posterior segment of the right lung and a swollen right interlobar lymph node.
  • Right lung pneumonectomy and node dissection were performed.
  • A histological diagnosis determined that the tumor was a large-cell carcinoma at clinical stage IIA.
  • Immunohistochemical analysis detected the production of carcinoembryonic antigen by the tumor cells.
  • This is a rare case of lung cancer with no evidence of recurrence and metastasis for 8 years despite markedly elevated preoperative carcinoembryonic antigen levels.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Carcinoma, Large Cell / immunology. Lung Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):51-60 [9511851.001]
  • [Cites] Nihon Rinsho. 2000 May;58(5):1127-31 [10824561.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):174-9 [12118753.001]
  • [Cites] Eur Respir J. 1991 Mar;4(3):374-6 [1650709.001]
  • [Cites] Int J Oncol. 2000 Jan;16(1):49-53 [10601548.001]
  • [Cites] Ann Thorac Surg. 2003 Mar;75(3):973-80 [12645726.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):677-82 [10717234.001]
  • [Cites] Tumour Biol. 1995;16(1):23-31 [7863219.001]
  • [Cites] Ann Thorac Surg. 1994 Sep;58(3):811-4 [7944708.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2004 Apr;10(2):76-80 [15209547.001]
  • (PMID = 17554998.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


70. Gan MF, Lu HS, Zhang JW, Yu XR: [Interdigitating dendritic cell sarcoma/tumor: a study of 3 cases]. Zhonghua Bing Li Xue Za Zhi; 2008 Oct;37(10):676-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdigitating dendritic cell sarcoma/tumor: a study of 3 cases].
  • OBJECTIVE: To study the pathologic features, diagnosis and differential diagnosis of interdigitating dendritic cell sarcoma (IDCS).
  • The site of occurrence included lung, spleen (with lymph node metastasis) and lymph node.
  • Histologically, the tumor cells were arranged in nests, fascicles and whorls, with intimate admixture of many lymphocytes and plasma cells.
  • They were oval to spindle in shape and contained pale eosinophilic cytoplasm, oval and sometimes grooved nuclei, small distinct nucleoli and ill-defined cell borders.
  • Immunohistochemical study showed that the tumor cells expressed S-100 protein.
  • CONCLUSIONS: IDCS is a rare type of histiocytic and dendritic cell malignancy with distinctive morphologic findings.
  • It needs to be distinguished from follicular dendritic cell sarcoma, inflammatory pseudotumor, Langerhans' cell histiocytosis, malignant melanoma, undifferentiated carcinoma and anaplastic large cell lymphoma.
  • Immunohistochemical staining for S-100 protein is helpful in confirming the diagnosis.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / pathology. Dendritic Cell Sarcoma, Interdigitating / pathology. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. S100 Proteins / immunology
  • [MeSH-minor] Adolescent. Carcinoma / pathology. Dendritic Cells / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094486.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


71. Granato F, Voltolini L, Ghiribelli C, Luzzi L, Tenconi S, Gotti G: Surgery for bronchogenic cysts: always easy? Asian Cardiovasc Thorac Ann; 2009 Oct;17(5):467-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients suffered iatrogenic injury of the contralateral main bronchus during excision of a mediastinal cyst; in one of them, late development of foreign body granuloma was related to migration towards the bronchial wall of cyanoacrylate used to reinforce suturing of the bronchial tear.
  • Histological examination of one resected specimen showed a large-cell anaplastic carcinoma arising from the wall of a mediastinal bronchogenic cyst.
  • [MeSH-major] Bronchogenic Cyst / surgery. Carcinoma, Large Cell / etiology. Granuloma, Foreign-Body / etiology. Iatrogenic Disease. Lung Neoplasms / etiology. Pulmonary Surgical Procedures / adverse effects. Thoracic Surgery, Video-Assisted / adverse effects. Thoracotomy / adverse effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917786.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Cyanoacrylates
  •  go-up   go-down


72. Nakazato Y, Imai K, Abe T, Tamura N, Shimazu K: Unpleasant sweet taste: a symptom of SIADH caused by lung cancer. J Neurol Neurosurg Psychiatry; 2006 Mar;77(3):405-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unpleasant sweet taste: a symptom of SIADH caused by lung cancer.
  • A 56 year old woman with large cell lung carcinoma complained of an unpleasant sweet taste (dysgeusia).
  • [MeSH-major] Carcinoma, Large Cell / diagnosis. Dysgeusia / etiology. Hyponatremia / complications. Inappropriate ADH Syndrome / etiology. Lung Neoplasms / diagnosis. Taste
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Reference Values. Sodium / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1968 Sep 20;161(3847):1241-3 [5673432.001]
  • [Cites] N Engl J Med. 1983 Jun 2;308(22):1337-43 [6341845.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Dec;21(4):859-75 [1486879.001]
  • [Cites] Sci Am. 2001 Mar;284(3):32-9 [11234504.001]
  • [Cites] J Clin Invest. 1963 May;42(5):727-35 [16695903.001]
  • [Cites] Arch Intern Med. 1995 Jun 26;155(12):1325-8 [7778965.001]
  • [Cites] Nature. 1969 Jun 21;222(5199):1176-9 [5788986.001]
  • [Cites] Am J Emerg Med. 2003 Nov;21(7):604-5 [14655244.001]
  • [Cites] Cancer. 1975 Nov;36(5):1888-96 [1192373.001]
  • [Cites] J Gen Physiol. 1988 Jul;92(1):87-111 [3171536.001]
  • [Cites] J Gen Physiol. 1990 May;95(5):1007-18 [2362181.001]
  • [Cites] Thorax. 2004 Jan;59(1):84 [14694261.001]
  • [Cites] N Engl J Med. 1983 May 26;308(21):1275-9 [6341841.001]
  • [Cites] J Am Diet Assoc. 1983 Nov;83(5):578-80 [6630821.001]
  • (PMID = 16484655.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9NEZ333N27 / Sodium
  • [Other-IDs] NLM/ PMC2077685
  •  go-up   go-down


73. Swarts JC, Vosloo TG, Cronje SJ, Du Plessis WC, Van Rensburg CE, Kreft E, Van Lier JE: Cytotoxicity of a series of ferrocene-containing beta-diketones. Anticancer Res; 2008 Sep-Oct;28(5A):2781-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity of a series of ferrocene-containing beta-diketones.
  • In contrast, reduced ferrocene derivatives frequently only show activity if cell components can oxidise them inside cells to the ferrocenium species.
  • MATERIALS AND METHODS: Ferrocene-containing beta-diketones of the type FcCOCH2COR with Fc=ferrocenyl and R=CF3, CCl3, CH3, Ph(=C6H5, phenyl) and Fc, were tested for cytotoxicity against HeLa (human cervix epitheloid), COR L23 (human large cell lung carcinoma) and platinum resistant CoLo320DM (human colorectal) and COR L23/CPR cancer cell lines.
  • Cell survival was measured by means of the colorometric 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) assay.
  • RESULTS: The mean drug concentration from 3 experiments causing 50% cell growth inhibition, (IC50) values, varied between 4.5 and 85.0 micromol dm(-3'), with the CF3(-) containing beta-diketone being the most active.
  • Drug activity was inversely proportional to the formal reduction potential, Eo', of the ferrocenyl group, and dependent on the R group in the general beta-diketone structure.
  • The CF3 complex was more cytotocic than cisplatin inter alia against platinum-resistant cell lines, and at least eight times more reactive against cancer cell lines than against PHA (phytohaemagglutinin)-stimulated lymphocyte cultures.

  • Hazardous Substances Data Bank. FERROCENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035310.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferrous Compounds; 0 / Ketones; 0 / Phytohemagglutinins; 12125-80-3 / ferrocenium; U96PKG90JQ / ferrocene
  •  go-up   go-down


74. Bai XY, Shen H: [Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct;26(10):1423-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray].
  • OBJECTIVE: To investigate thyroid transcription factor-1 (TTF-1) expression in normal human adult type II alveolar epithelial cells, embryonic pneumocytes, lung carcinoma cells and lymph node metastases of lung cancer.
  • METHODS: Lung carcinoma tissue microarray was constructed containing 765 cores of 20 normal adult lung tissues, 15 embryonic lung tissues, 100 lung carcinomas and 55 corresponding lymph node metastases.
  • RESULTS: The number TTF-1 positive units (PU) was smaller in the nuclei of embryonic pneumocytes than in those of normal adult type II alveolar epithelial cells (P<0.001).
  • The nuclei of lung carcinoma cells had smaller TTF-1 PU than normal adult type II alveolar epithelial cells and embryonic pneumocyte nuclei (P<0.001).
  • The lung adenocarcinoma and small cell lung carcinoma cell nuclei had greater TTF-1 PU than squamous cell carcinoma and large cell lung carcinoma cell nuclei (P<0.001).
  • TTF-1 PU was greater in squamous cell carcinoma cell nuclei than in large cell lung carcinoma cell nuclei (P<0.001).
  • In lung adenocarcinoma, squamous cell lung carcinoma and large cell lung carcinoma, TTF-1 PU was greater in the cancerous cell nuclei of lymph node metastases than in the corresponding primary carcinoma cell nuclei (P<0.001, P<0.001, and P<0.05, respectively).
  • In small cell lung carcinoma, TTF-1 PU of the cancerous cell nuclei of lymph node metastases was similar to that of primary carcinomas (P>0.05).
  • TTF-1 PU was greater in lung carcinoma with lymph node metastases than in those without metastalsis (P<0.001).
  • TTF-1 PU of the cell nuclei was not associated with the tumor growth pattern, differentiation and patients' gender (P>0.05), but was greater in TNM stage II-IV than in stage I (P<0.001).
  • CONCLUSIONS: The amount of TTF-1 in the cell nuclei decreases in the order of normal adult type II alveolar epithelial cells, embryonic pneumocytes and lung carcinoma cells.
  • TTF-1 expression is higher in adenocarcinoma and small cell carcinoma and lower in squamous carcinoma and large cell carcinoma.
  • Stronger TTF-1 expression is associated with greater likeliness of lung carcinoma metastatie, and can be an important hallmark for metastasis potential of lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
  • [MeSH-major] Cell Nucleus / metabolism. Lung Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Tissue Array Analysis / methods. Transcription Factors / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062341.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


75. Kasuganti D, Cimbaluk D, Gattuso P: Lymph node metastasis of large-cell carcinoma of the lung in a seventeen-year-old patient: diagnosis by fine-needle aspiration. Diagn Cytopathol; 2006 Dec;34(12):852-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node metastasis of large-cell carcinoma of the lung in a seventeen-year-old patient: diagnosis by fine-needle aspiration.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17115438.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down


76. Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M: Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol; 2009 May;22(5):709-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung.
  • Lung cancer classification in small-cell and non-small-cell types was recently challenged by data on the differential efficacy of new cytotoxic agents in specific histotypes.
  • An accurate histotype definition has therefore gained interest in both preoperative and surgical materials, but is a hard task especially in undifferentiated large-cell tumors lacking morphological signs of squamous or glandular differentiation.
  • On the basis of gene expression profiling data, reporting a remarkable differential expression of desmocollin-3 (a protein localized in desmosomal junctions of stratified epithelial) between adeno- and squamous cancers, we immunostained 62 cases of resected undifferentiated large-cell lung carcinomas for desmocollin-3 (and for TTF-1, p63 and mucin stain), to test its ability to identify a (residual) squamous phenotype, if present.
  • Desmocollin-3 was expressed in almost half of the undifferentiated large-cell cancers and was mutually exclusive with TTF-1 (positive in 39%; the remaining 18 % of cases was double negative).
  • Special large-cell carcinoma variants expressed desmocollin-3 in 6 of 6 basaloid, 7 of 12 clear-cell types, again mutually exclusive with TTF-1 expression.
  • In 31 cytological samples diagnosed as 'non-small-cell lung carcinoma', desmocollin-3 was again mutually exclusive with TTF-1 and stained all squamous carcinomas, 1 of 19 adenocarcinoma only, and 50% of large-cell carcinoma (all histologically confirmed).
  • This combined morphophenotypic approach may represent a valid adjunct (for both surgical and cytological samples) in the selection of patients with lung cancer to medical treatments tailored according to different efficacy in different lung carcinomas of the squamous, adeno- and large-cell types.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Desmocollins / biosynthesis. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287461.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / DSC3 protein, human; 0 / Desmocollins; 0 / TTF1 protein, human
  •  go-up   go-down


77. Liao L, Zhou Q, Chen J, Zhu D, Ma L, Yan H, Zhu W, Liu H: [Construction and screening of the subtracted cDNA library of human large cell lung cancer lines with different metastatic potentials]. Zhongguo Fei Ai Za Zhi; 2007 Jun 20;10(3):163-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Construction and screening of the subtracted cDNA library of human large cell lung cancer lines with different metastatic potentials].
  • BACKGROUND: Screening metastatic-related genes of lung cancer is helpful to understand the molecular mechanisms of lung cancer invasion and metastasis.
  • In order to screen the differential expression genes related to metastasis of lung cancer, we constructed and preliminarily screened the subtracted cDNA libraries of human large cell lung cancer cell lines with different metastatic potentials in this study.
  • METHODS: Subtracted cDNA library was constructed in the different metastastic potential cell lines NL9980 and L9981 by suppression subtractive hybridization (SSH) method.
  • RESULTS: The subtracted cDNA libraries were successfully constructed in the different metastastic potential cell lines NL9980 and L9981.
  • The forward and reverse subtracted cDNA libraries of different metastastic potential cell lines are constructed by this method.
  • The differential expression genes related to tumor metastasis might exist in the human large cell lung cancer cell lines with different metastasis potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118638.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


78. Sozzi G, Martelli MP, Conte D, Modena P, Pettirossi V, Pileri SA, Falini B: The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. Haematologica; 2009 Sep;94(9):1307-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ALK+ anaplastic large cell lymphoma and a rare subset of ALK+ diffuse large B-cell lymphoma.
  • Recently, rearrangements involving ALK and the echinoderm microtubule associated protein-like 4 (EML4) gene were described as a specific genetic alteration in about 6% of non-small cell lung cancer (NSCLC).
  • EML4-ALK transcripts were detected in 3/51 (5.9%) of reactive lymphoid tissues and 12/58 (20.7%) of lymphomas of different categories, including follicular lymphoma, diffuse large B-cell lymphoma and Hodgkin's disease.
  • [MeSH-minor] Animals. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Humans. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Mice. NIH 3T3 Cells

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1995 Jan 14;345(8942):87-90 [7815887.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4668-76 [9616164.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):875-86 [9736036.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1657-63 [10362790.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6618-24 [18927303.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 [19064915.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):661-70 [19147828.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1901-2 [11263444.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3509-15 [10552961.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2185-93 [11395396.001]
  • [Cites] Blood. 2002 Jan 15;99(2):409-26 [11781220.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • (PMID = 19734424.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  • [Other-IDs] NLM/ PMC2738726
  •  go-up   go-down


79. Bergner A, Kellner J, Tufman A, Huber RM: Endoplasmic reticulum Ca2+-homeostasis is altered in Small and non-small Cell Lung Cancer cell lines. J Exp Clin Cancer Res; 2009;28:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoplasmic reticulum Ca2+-homeostasis is altered in Small and non-small Cell Lung Cancer cell lines.
  • BACKGROUND: Knowledge of differences in the cellular physiology of malignant and non-malignant cells is a prerequisite for the development of cancer treatments that effectively kill cancer without damaging normal cells.
  • We aimed to investigate if the endoplasmic reticulum (ER) Ca2+-homeostasis is different in lung cancer and normal human bronchial epithelial (NHBE) cells.
  • RESULTS: In a Small Cell Lung Cancer (H1339) and an Adeno Carcinoma Lung Cancer (HCC) cell line but not in a Squamous Cell Lung Cancer (EPLC) and a Large Cell Lung Cancer (LCLC) cell line the ER Ca2+-content was reduced compared to NHBE.
  • Lowering the ER Ca2+-content with CPA led to increased proliferation NHBE and lung cancer cells.
  • CONCLUSION: The significant differences in Ca2+-homeostasis between lung cancer and NHBE cells could represent a new target for cancer treatments.
  • [MeSH-major] Calcium / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Endoplasmic Reticulum / metabolism. Lung Neoplasms / metabolism. Small Cell Lung Carcinoma / metabolism
  • [MeSH-minor] Calcium-Binding Proteins / metabolism. Cell Line, Tumor. Homeostasis. Humans. Immunohistochemistry. Microscopy, Fluorescence. Sarcoplasmic Reticulum Calcium-Transporting ATPases / metabolism


80. Petersen I, Kotb WF, Friedrich KH, Schlüns K, Böcking A, Dietel M: Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters. Lung Cancer; 2009 Sep;65(3):312-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters.
  • We attempted to establish a microscopy based tumour characterization providing insight into the genetics of cancer cells and in particular their DNA ploidy.
  • This classification was applied to 155 lung cancer samples from all major histologic types and the results were correlated with the analysis by DNA image cytometry and patient survival.
  • The morphological assessments correlated highly significantly with the DNA ploidy parameters, e.g. small cell lung carcinomas showed the smallest values for nuclear size (mean core score of 1.18) and DNA content (DNA index mean of 2.08c) being highly significantly different from adenocarcinomas (1.95/3.10c), large cell lung carcinoma (2.00/3.26c) and squamous cell carcinoma (2.20/3.42c).
  • In non-small cell lung carcinoma (NSCLC) in general and adenocarcinoma in particular, the core size variability correlated significantly with grading and survival.
  • As a complement to histologic tumour diagnosis the core classification should help to better stratify cancer subtypes.
  • [MeSH-major] Cell Nucleus / ultrastructure. DNA, Neoplasm / analysis. Lung Neoplasms / classification. Lung Neoplasms / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168259.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


81. Yang CJ, Huang YJ, Wang CY, Wang PH, Hsu HK, Tsai MJ, Chen YC, Bharath Kumar V, Huang MS, Weng CF: Antiproliferative effect of Toona sinensis leaf extract on non-small-cell lung cancer. Transl Res; 2010 Jun;155(6):305-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiproliferative effect of Toona sinensis leaf extract on non-small-cell lung cancer.
  • However, their effect against cancer cells is not well explored.
  • In this study, to understand the cytotoxic effect and molecular mechanism stimulated by TSL-1 (TS leaf extract fraction) we employed three different non-small-cell lung cancer (NSCLC) cell lines: H441 cells (lung adenocarcinoma), H661 cells (lung large cell carcinoma) and H520 cells (lung squamous cell carcinoma).
  • IC50 value was varied between these three cell lines, the least IC(50) value was observed in TSL-1-treated H661cells.
  • Exposure of NSCLC cells to TSL-1 caused cell-cycle arrest in subG1 phase and caused apoptosis.
  • Moreover, TSL-1 treatment decreased the cell-cycle regulators; cyclin D1 and CDK4 proteins by up regulating p27 expression in a dose-dependent manner.
  • Thus, the TSL-1-induced apoptosis was further confirmed by cell morphology, subG1 peak accumulation, poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) cleavage, propidium iodide (PI)-Annexin-V double staining, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay.
  • The decreased Bcl2 protein level was concurrent with an increased Bax protein level in all 3 cell lines.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Plant Extracts / therapeutic use. Plant Leaves / chemistry
  • [MeSH-minor] Animals. Apoptosis / drug effects. Carcinoma, Squamous Cell / pathology. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Female. G1 Phase / drug effects. Humans. Male. Mice. Mice, Nude


82. Ye S, Feng Z, Zhu W, Cai C, Li L, Sun L, Wan H, Ma L, Zhou Q: [Construction of the suppression subtractive cDNA libraries of human large cell lung cancer line L9981 before and after transfection with nm23-H1 gene.]. Zhongguo Fei Ai Za Zhi; 2008 Aug 20;11(4):482-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Construction of the suppression subtractive cDNA libraries of human large cell lung cancer line L9981 before and after transfection with nm23-H1 gene.].
  • BACKGROUND: It has been proven that nm23-H1 gene is an important metastaticsuppressed gene of lung cancer.
  • In order to screen the differential expression genes related to nm23-H1 , we constructed the suppression subtractive cDNA libraries of human large cell lung cancer line L9981 transfected and untransfected with nm23-H1 gene by suppression subtractive hybridization (SSH) in this study, which lay a solid foundation for further screening and cloning metastatic-related genes of nm23-H1.
  • METHODS: The forward and reverse suppression subtractive cDNA libraries were constructed in the human large cell lung cancer line L9981 before and after transfection with nm23-H1 gene (L9981 and L9981-nm23-H1) by SSH method.
  • RESULTS: The suppression subtractive cDNA libraries were successfully constructed in the human large cell lung cancer line L9981 transfected and untransfected with nm23-H1 gene (L9981-nm23-H1 and L9981).
  • The forward and reverse suppression subtractive cDNA libraries of human large cell lung cancer line L9981 transfected and untransfected with nm23-H1 gene (L9981-nm23-H1 and L9981) are successfully constructed by SSH and T/A cloning technology.
  • The expression of nm23-H1 gene in the human large cell lung cancer cell lines may affect the differential expression of some metastatic-related genes.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20735954.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


83. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, Fong Y, Wong RJ: Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab; 2008 Nov;93(11):4403-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo.
  • CONTEXT: Anaplastic thyroid carcinoma (ATC) is a fatal disease with a median survival of only 6 months.
  • OBJECTIVE: A mutated, replication-competent, vaccinia virus (GLV-1h68) has oncolytic effects on human ATC cell lines in vitro.
  • We assessed the utility of GLV-1h68 in treating anaplastic thyroid cancer in vivo.
  • At d 10, tumor viral recovery was increased more than 50-fold as compared with the injected dose, and minimal virus was recovered from the lung, liver, brain, heart, spleen, and kidneys.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Carcinoma / immunology. Thyroid Neoplasms / immunology. Vaccinia virus / immunology. Viral Vaccines / therapeutic use
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Line, Tumor. Genetic Markers. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous. Viral Plaque Assay

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Surgery. 2002 Mar;131(3):245-8 [11894027.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1848-53 [12085174.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):313-20 [14990953.001]
  • [Cites] Expert Opin Biol Ther. 2004 Aug;4(8):1307-21 [15268664.001]
  • [Cites] World J Surg. 1998 Jul;22(7):725-30 [9606289.001]
  • [Cites] Lancet. 1973 Mar 24;1(7804):656-9 [4121857.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2155-60 [3902203.001]
  • [Cites] J Endocrinol Invest. 1991 Jun;14(6):475-80 [1723086.001]
  • [Cites] Surgery. 2007 Dec;142(6):976-83; discussion 976-83 [18063085.001]
  • [Cites] Mol Ther. 2005 Feb;11(2):180-95 [15668130.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):10038-46 [17942938.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):525-32 [15382081.001]
  • (PMID = 18697871.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009685
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Genetic Markers; 0 / Viral Vaccines
  • [Other-IDs] NLM/ PMC3728375
  •  go-up   go-down


84. Pardo J, Martinez-Peñuela AM, Sola JJ, Panizo A, Gúrpide A, Martinez-Peñuela JM, Lozano MD: Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol; 2009 Oct;17(5):383-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell carcinoma of the lung: an endangered species?
  • This study aims to evaluate large cell carcinomas (LCC) of the lung with a panel of immunohistochemical markers in an attempt to identify tumors belonging to other categories.
  • The tumors were 82 (81.3%) classic LCC, 7 (6.9%) neuroendocrine LCC, 6 (5.9%) lymphoepithelioma-like LCC, 3 (2.9%) basaloid LCC, 2 (2%) clear cell LCC, and 1 (1%) LCC with rhabdoid phenotype.
  • Characteristic classic LCC immunophenotype was loss of staining with CK5/6, CK14 positive in most squamous cell carcinoma (SCC), lack of MOC 31 positive in most adenocarcinomas, and positive immunoreactivity to EGFR, PDGFR-alpha and c-kit.
  • 16 (19.5%) of 82 classic LCC correspond to undifferentiated adenosquamous carcinomas, since they displayed conflicting immunostaining for markers of both SCC and adenocarcinomas.
  • The use of 7 immunohistochemical markers, consisting of TTF-1, CK7, CK19, p63, 34betaE12, thrombomodulin, and CD44v6, markedly reduces dramatically to less than 10%, the number of classic LCC by readily identifying cases of poorly differentiated SCCs, adenosquamous carcinoma and adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444077.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


85. Sato K, Waseda R, Tatsuzawa Y, Soma R, Ueda Y, Katsuda S: Papillary thyroid carcinoma with anaplastic transformation showing a rhabdoid phenotype solely in the cervical lymph node metastasis. Pathol Res Pract; 2006;202(1):55-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary thyroid carcinoma with anaplastic transformation showing a rhabdoid phenotype solely in the cervical lymph node metastasis.
  • We describe a rare case of anaplastically transformed papillary thyroid carcinoma with a rhabdoid phenotype appearing solely in a metastatic focus.
  • Examination of surgically resected specimens disclosed that the thyroid tumor was a well-differentiated papillary carcinoma (2.0 cm in diameter), and the right lateral cervical mass was an anaplastic carcinoma (2.4 cm in diameter) showing a rhabdoid phenotype with scant amounts of a papillary carcinoma component in the periphery, considered to be transformed through the metastasis of the papillary thyroid carcinoma in a cervical lymph node.
  • The rhabdoid cells had eccentric nuclei with conspicuous nucleoli and spherical hyaline cytoplasmic inclusions, which are immunoreactive for vimentin and sarcomeric actin.
  • [MeSH-major] Carcinoma, Papillary / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Aged. Biomarkers, Tumor. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymph Nodes. Lymphatic Metastasis. Male. Rhabdoid Tumor

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310972.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


86. Zhang Z, Fan Y, Zhou Q, Wang Y, Ma L, Chen X, Zhu W, Yang X, Zhao Y: [Effects of polysaccharid on expression of angiogenic-related genes in human high-metastatic large cell lung cancer cell line L9981]. Zhongguo Fei Ai Za Zhi; 2006 Apr 20;9(2):137-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of polysaccharid on expression of angiogenic-related genes in human high-metastatic large cell lung cancer cell line L9981].
  • BACKGROUND: Lung cancer is one of the most malignant cancers which is hazarding the people's health and life in the world.
  • The aim of this study is to observe the effects of polysaccharid (PS-T) on expression of angiogenic-related gene mRNA in human high-metastatic large cell lung cancer cell line L9981, and to explore its possible molecular mechanism.
  • CONCLUSIONS: (1)PT-S could inhibit the growth of human high-metastatic large cell lung cancer cell line L9981 in vitro, the effect is dose-dependent. (2)PS-T can down- or up-regulate the mRNA transcript expression of some angiogenic-related gene mRNA. (3)PS-T has remarkably coordinating effects with cisplatin in the L9981 lung cancer cell line.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21144298.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


87. Zou LJ, Li GQ, Gong LL, Wang Y, Jin W, Zhao JY, Ma HY, Yang PM, Shao SJ: [Expression of aurora-A kinase in human lung cancer cell lines PG, A549, and NCI-H460]. Ai Zheng; 2005 Jul;24(7):792-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of aurora-A kinase in human lung cancer cell lines PG, A549, and NCI-H460].
  • This study was to detect the expression of Aurora-A in lung cancer cell lines PG (highly-metastatic giant cell lung cancer), A549 (lung adenocarcinoma), and NCI-H460 (large cell lung cancer) and explore its correlation to DNA content, provide a theoretical basis for screening tumor marker and molecular therapeutic target of lung cancer.
  • METHODS: mRNA and protein levels of Aurora-A in PG, A549, and NCI-H460 cells were detected by reverse transcription-polymerase chain reaction(RT-PCR) and Western blot.
  • Flow cytometry was used to analyze DNA contents in cell cycles of PG, A549, and NCI-H460 cells.
  • RESULTS: mRNA level of Aurora-A was 1.14 in PG cells, 1.16 in A549 cells, and 0.84 in NCI-H460 cells, respectively; protein level of Aurora-A was 8.96 in PG cells, 21.13 in A549 cells, and 6.43 in NCI-H460 cells, respectively.
  • The proportion of cells with tetraploid DNA was 19.88% in PG cells, 14.97% in A549 cells, and 10.6% in NCI-H460 cells, respectively (P<0.01); the proportion of cells with polyploid DNA was 2.66% in PG cells, 3.59% in A549 cells, and 2.30% in NCI-H460 cells, respectively.
  • CONCLUSION: Aurora-A is overexpressed in the 3 lung cancer cell lines, but the mRNA levels are different.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Giant Cell / metabolism. Carcinoma, Large Cell / metabolism. Lung Neoplasms / metabolism. Protein-Serine-Threonine Kinases / biosynthesis
  • [MeSH-minor] Aurora Kinases. Cell Line, Tumor. DNA, Neoplasm / genetics. Humans. Polyploidy. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004802.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Messenger; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


88. Buendia AJ, Sánchez J, Martinez CM, Navarro JA: Immunohistochemical characterization of a pulmonary large-cell carcinoma in a dog. Vet Pathol; 2008 Jul;45(4):484-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical characterization of a pulmonary large-cell carcinoma in a dog.
  • Pulmonary large-cell carcinoma is considered extremely rare in domestic animals, and some of the few reported cases actually may have been cases of malignant pulmonary histiocytosis.
  • Histologically, pulmonary alveolar spaces contained clusters of large round anaplastic cells with ample eosinophilic cytoplasm and large irregularly shaped nuclei with prominent nucleoli.
  • Immunohistochemistry was used to distinguish large-cell carcinoma from malignant pulmonary histiocytosis.
  • Tumor cells had strong immunoreactivity for cytokeratin, consistent with epithelial origin.
  • However, a substantial percentage of the neoplastic cells co-expressed vimentin and MHC-II.
  • The type II alveolar epithelial cell was considered the cell of origin of the neoplasm based on the presence of lamellar bodies in some neoplastic cells and immunoreactivity for surfactant protein A and thyroid transcription factor-1.
  • [MeSH-major] Carcinoma, Large Cell / veterinary. Dog Diseases / pathology. Lung Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587094.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA: Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol; 2010 Nov 1;28(31):4769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
  • In patients with metastatic colorectal cancer, the predictive value of KRAS mutational status in the selection of patients for treatment with anti-epidermal growth factor (EGFR) monoclonal antibodies is established.
  • In patients with non-small-cell lung cancer (NSCLC), the utility of determining KRAS mutational status to predict clinical benefit to anti-EGFR therapies remains unclear.
  • Unlike colorectal cancer, KRAS mutations do not seem to identify patients who do not benefit from anti-EGFR monoclonal antibodies in NSCLC.
  • The future value of testing for KRAS mutational status may be to exclude the possibility of an EGFR mutation or anaplastic lymphoma kinase translocation or to identify a molecular subset of patients with NSCLC in whom to pursue a drug development strategy that targets the KRAS pathway.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Mutation. Precision Medicine. Proto-Oncogene Proteins / metabolism. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. ras Proteins / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Carboplatin / pharmacology. Cell Cycle Proteins / genetics. Cetuximab. Cisplatin / pharmacology. Clinical Trials as Topic. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology. Erlotinib Hydrochloride. Humans. Microtubule-Associated Proteins / genetics. Paclitaxel / pharmacology. Patient Selection. Predictive Value of Tests. Protein-Tyrosine Kinases / genetics. Quinazolines / pharmacology. Receptor Protein-Tyrosine Kinases. Serine Endopeptidases / genetics. Signal Transduction. Survival Analysis. Translocation, Genetic

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20921461.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / KRAS protein, human; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.4.21.- / EML4 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.6.5.2 / ras Proteins; P88XT4IS4D / Paclitaxel; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; S65743JHBS / gefitinib
  •  go-up   go-down


90. Pavićević R, Bubanović G, Franjević A, Stancić-Rokotov D, Samarzija M: CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis. Coll Antropol; 2008 Jun;32(2):485-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
  • Standardisation is achieved by determining the reference range in asymptomatic population, benign and malignant lung diseases, and benign and malignant diseases of other organs.
  • The cut-off level of CYFRA 21-1 for non-small cell lung cancer (NSCLC) is 1.72 ng/mL in the Croatian population.
  • It is based on the clinically applicable sensitivity of 78% and specificity of 95% in benign lung diseases.
  • For clinicians the level of CYFRA 21-1 is an early sign of NSCLC in relation to all the benign lung diseases and all the benign diseases of other organs, of which it was confirmed that they can influence the above level, provided that NSCLC is verified using standard diagnostic methods.
  • The sensitivity of CYFRA 21-1 in NSCLC is 78%, in squamous cell lung cancer (SQC) 84.6%, in adenocarcinomas (AD) 74.3% and in large cell lung cancer (LCC) 75.3%.
  • The level of CYFRA 21-1 prompts clinicians to repeat the clinical procedure during diagnosis, and helps to detect the disease earlier and implement treatment in NSCLC.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Keratins / blood. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756899.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


91. Roy PP, Basu N: Bilateral adrenal metastases from large cell carcinoma of lung in a female non-smoker patient. J Assoc Physicians India; 2006 Jun;54:504-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral adrenal metastases from large cell carcinoma of lung in a female non-smoker patient.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Large Cell / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912999.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] India
  •  go-up   go-down


92. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R: Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol; 2008 Feb;21(2):192-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study is to evaluate the expressions of these markers in thyroid tumors of the full spectrum of differentiation, with special emphasis on anaplastic carcinomas.
  • A total of 94 cases of thyroid neoplasms were studied: 17 papillary carcinomas, 18 follicular adenomas, 16 follicular carcinomas, 7 poorly differentiated carcinomas, 28 anaplastic carcinomas, and 8 medullary carcinomas.
  • The antibodies to Pax8 and TTF-2 were also applied on 147 lung carcinomas as well as a variety of normal tissues and malignant tumors.
  • Pax8 was expressed in 79% of anaplastic carcinomas to a variable extent, whereas TTF-1 and TTF-2 were seen only in 18 and 7% of anaplastic carcinomas, respectively.
  • TTF-2 was negative in all other neoplastic and non-neoplastic tissues including those of the lung.
  • Pax8 was expressed in renal tubules, fallopian tubes, ovarian inclusion cysts, and lymphoid follicles as well as renal carcinoma, nephroblastoma, seminoma, and ovarian carcinoma, but not in normal tissue and carcinomas of the lung.
  • Pax8 is a useful marker for the diagnosis of anaplastic carcinomas, particularly when the differential diagnosis includes pulmonary carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Adenosine Triphosphatases / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / metabolism. DNA-Binding Proteins / metabolism. Paired Box Transcription Factors / metabolism. Thyroid Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Calcitonin / metabolism. Carcinoma / diagnosis. Carcinoma / metabolism. Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / metabolism. Female. Fluorescent Antibody Technique, Indirect. Humans. Hyperplasia. Immunoenzyme Techniques. Male. Middle Aged. Thyroid Gland / metabolism. Thyroid Gland / pathology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Calcitonin .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084247.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / Transcription Factors; 9007-12-9 / Calcitonin; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / TTF2 protein, human
  •  go-up   go-down


93. Nogales FF, Buriticá C, Regauer S, González T: Mucinous carcinoid as an unusual manifestation of endodermal differentiation in ovarian yolk sac tumors. Am J Surg Pathol; 2005 Sep;29(9):1247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor in the second case consisted of an AFP-positive glandular YST, with a glandulopapillary pattern closely resembling fetal lung type adenocarcinoma, coexisting with an AFP-negative, cytokeratin 20-positive, atypical MC; transitional areas between the two components were also seen.
  • AFP levels became negative during the course of disease paralleling the disappearance of the YST component and the overgrowth of an increasingly anaplastic MC.
  • The patient died 1 year after diagnosis.
  • It is important to differentiate the yolk sac and carcinoid components due to their different responses to chemotherapy and to evaluate the possibility of mucinous carcinoid developing into a highly aggressive carcinoma.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096416.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  •  go-up   go-down


94. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV: The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res; 2006 Feb 15;66(4):2153-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer.
  • The proliferation-specific Forkhead Box m1 (Foxm1 or Foxm1b) transcription factor (previously called HFH-11B, Trident, Win, or MPP2) regulates expression of cell cycle genes essential for progression into DNA replication and mitosis.
  • Expression of Foxm1 is found in a variety of distinct human cancers including hepatocellular carcinomas, intrahepatic cholangiocarcinomas, basal cell carcinomas, ductal breast carcinomas, and anaplastic astrocytomas and glioblastomas.
  • In this study, we show that human Foxm1 protein is abundantly expressed in highly proliferative human non-small cell lung cancers (NSCLC) as well as in mouse lung tumors induced by urethane.
  • To determine the role of Foxm1 during the development of mouse lung tumors, we used IFN-inducible Mx-Cre recombinase transgene to delete mouse Foxm1 fl/fl-targeted allele before inducing lung tumors with urethane.
  • We show that Mx-Cre Foxm1-/- mice exhibit diminished proliferation of lung tumor cells causing a significant reduction in number and size of lung adenomas.
  • Transient transfection experiments with A549 lung adenocarcinoma cells show that depletion of Foxm1 levels by short interfering RNA caused diminished DNA replication and mitosis and reduced anchorage-independent growth of cell colonies on soft agar.
  • Foxm1-depleted A549 cells exhibit reduced expression of cell cycle-promoting cyclin A2 and cyclin B1 genes.
  • These data show that Foxm1 stimulates the proliferation of tumor cells during progression of NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Forkhead Transcription Factors / physiology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Alleles. Animals. Cell Adhesion. Cell Growth Processes / physiology. Cyclin A / biosynthesis. Cyclin A / genetics. Cyclin A2. Cyclin B / biosynthesis. Cyclin B / genetics. Cyclin B1. DNA Replication. DNA, Neoplasm / biosynthesis. Gene Deletion. Humans. Mice. Mice, Inbred C57BL. Mice, Transgenic. Mitosis. RNA, Small Interfering / genetics. Urethane


95. Kohli PS, Soni NK: Nasal tip metastasis: an unusual site and mode of spread in anaplastic thyroid carcinoma. Indian J Otolaryngol Head Neck Surg; 2008 Sep;60(3):269-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal tip metastasis: an unusual site and mode of spread in anaplastic thyroid carcinoma.
  • Anaplastic thyroid carcinoma (ATC) is the most aggressive and lethal form of thyroid malignancy which is difficult to treat.
  • At the time of diagnosis, majority of patients have distant metastases most commonly in lung, bone, and liver.
  • Implantation of malignant cells on nasal tip is also unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1990 Jan;22(1):19-26 [2298962.001]
  • [Cites] Surg Gynecol Obstet. 1971 Oct;133(4):673-7 [4938079.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Jul;117(1):139 [9230343.001]
  • [Cites] Can J Surg. 2002 Jun;45(3):224-5 [12067183.001]
  • (PMID = 23120560.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450640
  • [Keywords] NOTNLM ; Implantation metastasis / Nasal metastasis / Thyroid carcinoma
  •  go-up   go-down


96. Ashidi JS, Houghton PJ, Hylands PJ, Efferth T: Ethnobotanical survey and cytotoxicity testing of plants of South-western Nigeria used to treat cancer, with isolation of cytotoxic constituents from Cajanus cajan Millsp. leaves. J Ethnopharmacol; 2010 Mar 24;128(2):501-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnobotanical survey and cytotoxicity testing of plants of South-western Nigeria used to treat cancer, with isolation of cytotoxic constituents from Cajanus cajan Millsp. leaves.
  • AIM OF STUDY: To document plants commonly used to treat cancer in South-western Nigeria and to test the scientific basis of the claims using in vitro cytotoxicity tests.
  • Three cancer cell lines (human breast adenocarcinoma cell line MCF-7, human large cell lung carcinoma cell line COR-L23 and human amelanotic melanoma C32) and one normal cell line (normal human keratinocytes SVK-14) were used for the screening of the extracts and the fractions obtained.
  • Pinostrobin and longistylins A and C were tested for cytotoxicity on the cancer cell lines.
  • In addition, an adriamycin-sensitive acute T-lymphoblastic leukaemia cell line (CCRF-CEM) and its multidrug-resistant sub-line (CEM/ADR5000) were used in an XTT assay to evaluate the activity of the pure compounds obtained.
  • The dichloromethane fraction of Cajanus cajan had IC(50) value 5-10 microg/mL, with the two constituent stilbenes, longistylins A and C, being primarily responsible, with IC(50) values of 0.7-14.7 microM against the range of cancer cell lines.
  • CONCLUSIONS: Most of the species tested had some cytotoxic effect on the cancer cell lines, which to some extent supports their traditional inclusion in herbal preparations for treatment of cancer.
  • However, little selectivity for cancer cells was observed, which raises concerns over their safety and efficacy in traditional treatment.
  • [MeSH-minor] Cell Line, Tumor. Data Collection. Ethnopharmacology. Flavanones / isolation & purification. Flavanones / toxicity. Humans. Male. Nigeria. Oleanolic Acid / analogs & derivatives. Oleanolic Acid / isolation & purification. Oleanolic Acid / toxicity. Plant Leaves / chemistry. Sitosterols / isolation & purification. Sitosterols / toxicity

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20064598.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Flavanones; 0 / Sitosterols; 0 / pinostrobin; 5LI01C78DD / gamma-sitosterol; 6SMK8R7TGJ / Oleanolic Acid; KM8353IPSO / amyrin
  •  go-up   go-down


97. Singh N, Srinivas R, Bal A, Aggarwal AN: Lung carcinoma mimicking hydatid cyst: a case report and review of the literature. Med Oncol; 2009 Dec;26(4):424-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung carcinoma mimicking hydatid cyst: a case report and review of the literature.
  • It is unusual for a malignant lung tumor to present clinically as a cystic lesion.
  • A case of large cell carcinoma of the lung mimicking pulmonary hydatid cyst is reported herein.
  • The patient was found to have positive serological test for Echinococcus granulosus and therefore the preoperative diagnosis was that of complicated pulmonary hydatid cyst.
  • Intra-operative findings included presence of a large cavity filled with necrotic material and "daughter cysts".
  • Histopathological evaluation of the excised specimen showed large cell carcinoma.
  • The case highlights the fact that a lung carcinoma may rarely have clinical, radiological, and serological features similar to those of a pulmonary hydatid cyst.
  • [MeSH-major] Carcinoma, Large Cell / diagnosis. Echinococcosis, Pulmonary / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Aged. Animals. Diagnosis, Differential. Echinococcosis / diagnostic imaging. Echinococcosis / pathology. Echinococcosis / surgery. Echinococcus granulosus. Humans. Male. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Respir J. 2003 Jun;21(6):1069-77 [12797504.001]
  • [Cites] Thorac Cardiovasc Surg. 1985 Aug;33(4):250-2 [2413580.001]
  • [Cites] Chest. 1993 Mar;103(3):983-4 [8383594.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jul;33(7):360-3 [12949064.001]
  • [Cites] Int J Gynaecol Obstet. 1992 Aug;38(4):315-6 [1358691.001]
  • [Cites] Am J Trop Med Hyg. 1999 Feb;60(2):193-8 [10072135.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2007 Jul;45(7):556-9 [17682467.001]
  • [Cites] Khirurgiia (Mosk). 1959 Jan;35(1):121-3 [13631872.001]
  • [Cites] Clin Chest Med. 2002 Jun;23(2):397-408, ix [12092034.001]
  • [Cites] J Coll Physicians Surg Pak. 2007 Jul;17(7):438-40 [17686364.001]
  • [Cites] Acta Chir Belg. 2007 Jun;107(3):328-30 [17685265.001]
  • [Cites] Chest. 1999 Jul;116(1):263-5 [10424541.001]
  • [Cites] Kyobu Geka. 2006 Nov;59(12):1099-102 [17094549.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2007 Mar;55(3):143-6 [17447515.001]
  • (PMID = 19067256.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


98. Khan N, Golzar J, Smith NL, Movahed A: Intracardiac extension of a large cell undifferentiated carcinoma of lung. Heart; 2005 Apr;91(4):512
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracardiac extension of a large cell undifferentiated carcinoma of lung.
  • [MeSH-major] Carcinoma, Large Cell / pathology. Lung Neoplasms / pathology. Myocardium / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772215.001).
  • [ISSN] 1468-201X
  • [Journal-full-title] Heart (British Cardiac Society)
  • [ISO-abbreviation] Heart
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1768849
  •  go-up   go-down


99. Li S, Han L, Sun L, Zheng D, Liu J, Fu Y, Huang X, Wang Z: Synthesis and antitumor activities of phenanthrene-based alkaloids. Molecules; 2009;14(12):5042-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of phenanthrene-based tylophorine derivatives (PBTs) were synthesized and their cytotoxic activities against the H460 human large-cell lung carcinoma cell line were evaluated.

  • Hazardous Substances Data Bank. PHENANTHRENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032876.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antineoplastic Agents; 0 / Phenanthrenes; 448J8E5BST / phenanthrene
  •  go-up   go-down


100. Zhu W, Deng Y, Zhou Q, Chen X, Wang Y, Liu L, Che G: [Analysis of two-dimension gel electrophoresis of human large cell lung cancer cell lines with different metastasis potentials]. Zhongguo Fei Ai Za Zhi; 2005 Feb 20;8(1):1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of two-dimension gel electrophoresis of human large cell lung cancer cell lines with different metastasis potentials].
  • BACKGROUND: Metastasis is not only the malignant characteristics of lung can- cer, but also the chief cause of failure to cure and high mortality of lung cancer.
  • To better explore and understand the mechanism of lung cancer metastasis and to search for potential markers for early diagnosing and reversing lung cancer metastasis, differential proteomic analysis is conducted in two human large cell lung cancer cell lines with high metastasis potentials (L9981) and low metastasis potentials (NL9980) by two-dimension gel electrophoresis (2-DE).
  • METHODS: The total proteins of the two cell lines were separated by immobilized pH gradient (IPG)-based 2-DE.
  • The differentially expressed proteins of the two cell lines were analyzed using image analysis software.
  • RESULTS: A high resolution and reproducible 2-DE image was successfully obtained.
  • The average total number of protein spots was 902±169 in L9981 cells and 941±173 in NL9980 cells in three repeated experiments.
  • Image analysis of siliver-stained 2-DE image revealed that 4 protein spots had significant differential expressions in L9981 and NL9980 (student's t-test, P < 0.05).
  • CONCLUSIONS: The results in this study suggest that an obviously differential proteomic expression exists between the human high- and low-metastatic large cell lung cancer cell lines.
  • It will be helpful to further understand the molecular mechanisms of lung cancer invasion and metastasis, and provide new experimental evidence for searching metastatic-related molecule of lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187015.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement